

INFORMAZIONI PERSONALI

Stefania Gori



📍 Via Don Angelo Sempreboni 5, 37024 Negrar di Valpolicella (VR), Italia

☎ +39 045 6013472

✉ stefania.gori@sacrocuore.it

Cittadinanza Italiana

Data e luogo di nascita 03/08/1956, Fabro (TR)

Codice fiscale GRO SFN 56M43 D454 F

Sesso Femminile

ESPERIENZA
PROFESSIONALE

Date	Dal 02 Febbraio 2017 ad oggi
Lavoro o posizione ricoperti	Direttore Medico Unità Clinica di Fase I Oncologia Medica
Nome e indirizzo del datore di lavoro	IRCCS Ospedale Sacro Cuore - Don Calabria – Via Don A. Sempreboni, 5 - 37024 - Negrar (VR)
Date	Dal 2013 ad oggi
Lavoro o posizione ricoperti	Direttore Dipartimento Oncologico
Nome e indirizzo del datore di lavoro	IRCCS Ospedale Sacro Cuore - Don Calabria – Via Don A. Sempreboni, 5 - 37024 - Negrar (VR)
Date	Da Marzo 2013 ad oggi
Lavoro o posizione ricoperti	Direttore UOC Oncologia Medica
Principali attività e responsabilità	Coordinatore di attività di reparto, Day Hospital, ambulatoriale, di guardie, di ricerca scientifica
Nome e indirizzo del datore di lavoro	IRCCS Ospedale Sacro Cuore - Don Calabria – Via Don A. Sempreboni, 5 - 37024 - Negrar (VR)
Tipo di attività o settore	Responsabile di UOC di Oncologia Medica
Date	Da Maggio 1987 a Febbraio 2013
Lavoro o posizione ricoperti	Dirigente Medico I livello
Principali attività e responsabilità	Attività di Day Hospital, ambulatoriale, di guardie, di ricerca scientifica
Nome e indirizzo del datore di lavoro	Ospedale Santa Maria della Misericordia – via G. Dottori, 1 -06132 - Perugia
Tipo di attività o settore	Medico Oncologo

ISTRUZIONE E FORMAZIONE

Date	Giugno 1988
Titolo della qualifica rilasciata	Diploma Scuola di Specializzazione in Oncologia Medica
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università di Pavia
Date	Luglio 1985
Titolo della qualifica rilasciata	Diploma Scuola di Specializzazione in Medicina Interna
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studi di Perugia
Date	Luglio 1980
Titolo della qualifica rilasciata	Laurea in Medicina e Chirurgia
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli studi di Perugia

COMPETENZE PERSONALI

Lingua madre Italiana

Altre lingue

COMPRESIONE		PARLATO		PRODUZIONE SCRITTA
Ascolto	Lettura	Interazione	Produzione orale	
C1	C1	B1	B1	C1
Sostituire con il nome del certificato di lingua acquisito. Inserire il livello, se conosciuto				

Livelli: A1/2 Livello base - B1/2 Livello intermedio - C1/2 Livello avanzato
Quadro Comune Europeo di Riferimento delle Lingue

Competenze e capacità sociali

Ottime capacità di relazionarsi e di creare un lavoro in équipe motivando i colleghi.

- Ha svolto dal 1981 al 1983 attività didattica presso la Scuola per Infermieri dell'Università degli Studi di Perugia
- Ha svolto dal 2001 al 2004 attività didattica presso la Facoltà di Medicina dell'università degli Studi di Perugia
- Membro dell'Associazione Italiana di Oncologia Medica (AIOM) dal 2000 con questi ruoli:
 - Tesoriere regionale AIOM dal 2000 al 2002
 - Coordinatore Regionale sez. Umbria dall'aprile 2002 all'aprile 2006
 - Membro del consiglio di Amministrazione di AIOM Servizi dal 2004 al 2007
 - Consigliere Nazionale dal 2007 al 2011
 - Tesoriere Nazionale dal 2011 al 2013
 - Segretario Nazionale da ottobre 2013 ad ottobre 2015
 - Presidente eletto da ottobre 2015 al 27 ottobre 2017
 - Presidente AIOM dal 28 ottobre 2017 al 27 ottobre 2019
 - Presidente Fondazione AIOM dal 1 novembre 2019 al 1 novembre 2021
- Presidente Rete Oncologica Pazienti Italia (ROPI) dall'11 dicembre 2021
- Presidente AIGOM- Associazione Italiana dei Gruppi Oncologici Multidisciplinari da dicembre 2022
- Socio ASCO
- Socio ESMO
- Socio AIOM
- Socio GOIRC

Competenze organizzative e gestionali

Ottime capacità di coordinamento di gruppi di lavoro:

- È stata Responsabile della Struttura Semplice di "Degenza Oncologica" presso la S. C. di Oncologia Medica dell'Ospedale Santa Maria della Misericordia di Perugia da Gennaio 2008 a Febbraio 2013
- Ha svolto attività con un'associazione di volontariato
- Ha fatto parte di commissioni tecnico scientifiche di vario grado
- Ha redatto la stesura di Protocolli sulla patologia mammaria
- Dal 2012 è coordinatrice delle Linee Guida Nazionali AIOM "Neoplasie mammarie"

Competenze informatiche

Ottimo utilizzo del PC (Programmi Office, Power Point, Internet)

Altre competenze

Redattore di articoli su tematiche relative alla sanità su quotidiani nazionali.

Ha redatto oltre 250 pubblicazioni di carattere scientifico su temi oncologici pubblicate su riviste indicizzate

Ha partecipato in qualità di relatore e/o moderatore a oltre 150 congressi (nazionali ed internazionali)

Ha conseguito numerosi attestati e diplomi in congressi nazionale e internazionali

Ha organizzato oltre 80 congressi scientifici nazionali e regionali relativi alla Patologia Mammaria e alle varie patologie oncologiche

Certificazioni

- Certificato di Esecutore di Advanced Life Support (n.°218838) rilasciato da Italian Resuscitation Council (IRC) nel mese di marzo 2017
- Certificato di Esecutore di Immediate Life Support (n° 622098) rilasciato da Italian Resuscitation Council (IRC) il 23/09/2020
- Certificato Good Clinical Practice (GCP training for HCPs v 2.0) del 14/01/2021
- Certificato Good Clinical Practice (GCP training for HCPs v 2.0) del 05/01/2022
- Certificato di Esecutore di Advanced Life Support (n.°1641756) rilasciato da Italian Resuscitation Council (IRC) nel mese di febbraio 2022
- Certificato Good Clinical Practice (ICH GCP E6R3) Training for Site Personnel v1.0, 01Jun2025 del 23/07/2025
- **Abilitazione Scientifica Nazionale alle funzioni di professore universitario di Seconda Fascia nel Settore Concorsuale 06/D3 - MALATTIE DEL SANGUE, ONCOLOGIA E REUMATOLOGIA.** La validità dell'Abilitazione è di dieci anni a decorrere dal 06/04/2017 e avrà scadenza il 06/04/2027.
- **Abilitazione Scientifica Nazionale alle funzioni di professore universitario di Prima Fascia nel Settore Concorsuale 06/D3 - MALATTIE DEL SANGUE, ONCOLOGIA E REUMATOLOGIA.** La validità dell'Abilitazione è di dieci anni a decorrere dal 31/10/2018 e avrà scadenza il 31/10/2028

ULTERIORI INFORMAZIONI

Pubblicazioni

1. **Gori S.** Danti E, Venti G, Mecucci C, Crinò L, Tonato M: Acute myeloblastic leukemia after adjuvant chemotherapy with melphalan in breast cancer. Case report with cytogenetic analysis. Tumori 69:117-122, 1983
2. Di Costanzo F, **Gori S**, Tonato M, Buzzi F, Crinò L, Grignani F, Davis S: Vindesine and mitomycin C in chemotherapy refractory advanced breast cancer. Cancer, 57: 904-907, 1986
3. Colozza M, **Gori S**, Mosconi AM, Belsanti V, Basurto C, Rossetti R, Di Costanzo F, Buzzi F, Bacchi M, Davis S, Tonato M. Chemotherapy with cis-Platin, Doxorubicin, and Cyclophosphamide (CAP) in patients with metastatic breast cancer. American Journal of Clinical Oncology, 12: 137-141, 1989.
4. Passalacqua R, Bisagni G, Bertusi M, Donati D, Buzzi F, Di Costanzo F, Basurto C, **Gori S**: Lomudamine in advanced colorectal cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC). TUMORI 1989; 75:277-279

5. Cocconi G, Bisagni G, Ceci G, Bacchi M, Brugia M, Carpi A, Di Costanzo F, Franciosi V, **Gori S**, Indelli M, Passalacqua R: Low-dose aminoglutetimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical research. *Journal of Clinical Oncology*, vol 10 (6),1992, pagg 984-989
6. Colozza M, **Gori S**, Mosconi A., Anastasi P, De Angelis V, Giansanti M, Mercati U, Aristei C, Latini P, Tonato M: Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long-term results. *Am. J. Clin. Oncol.* 19 (1): 10-17, 1996
7. Colozza M, **Gori S**, Mosconi AM, Anastasi P, Basurto C, Ludovini V, De Angelis V, Giansanti M, Tonato M: Salvage chemotherapy in metastatic breast cancer: an experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin. *Breast Cancer Research and Treatment* 38: 277-282, 1996
8. Colozza M, Mosconi AM, **Gori S**, Belsanti V, Basurto C, De Angelis V, Giansanti M, Tonato M: Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide. *American Journal of Oncology*, 20 (5):522-526,1997.
9. **Gori S**, Mosconi AM, Tabilio A, Falzetti F, Aristei, Basurto C, Cherubini R, Latini P, Martelli FM, Tonato M: Results of a prospective study with high-dose etoposide, thiotepa and carboplatin and peripheral blood stem cell rescue for high-risk stage II-IIIa and selected stage IV breast cancer patients. *TUMORI*, 87:138-141, 2001.
10. **Gori S**, Mosconi AM, Basurto C, Cherubini R, De Angelis V., Tonato M., Colozza M.: Weekly paclitaxel in metastatic breast cancer patients. A phase II study. *TUMORI* 88:470-473, 2002
11. Colozza M., Bisagni G., Mosconi A.M., **Gori S**., Boni C., Sabbatini R., Frassoldati A., Passalacqua R., Bian A. R., Rodinò C., Rondini E., Algeri R., Di Sarra S., De Angelis V., Cocconi G., Tonato M: Epirubicin vs CMF as adjuvant therapy of stage I and II of breast cancer: a prospective randomised study. *European Journal of Cancer* 38:2279-2288; 2002
12. Ludovini V, Sidoni A, Pistola L, Bellezza G, De Angelis V, **Gori S**, Mosconi AM, Bisagni G, Cherubini R, Bian AR, Rodinò C, Sabbatini R, Mazzocchi B, Bucciarelli E, Tonato M, Colozza: Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stage I and II breast cancer patients. *Breast Cancer Research and Treatment* 2003; 81:159-168
13. **Gori S**, Colozza M, Mosconi AM, Franceschi E, Basurto C, Cherubini R, Sidoni A, Rulli A, Bisacci C, De Angelis V, Crinò L, Tonato M: Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. *British Journal of Cancer* 2004; 90: 36-40
14. **Gori S**, Anastasi P, Marrocolo F. Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study] *Suppl Tumori*. 2004 Jul-Aug;3(4):S27-31.
15. Perrucci E, Aristei C, De Angelis V, Anselmo P, Mascioni F, **Gori S**, Frattegiani A, Latini P. T1-T2 breast cancer with four or more positive axillary lymph nodes: adjuvant locoregional radiotherapy with high-dose or standard-dose chemotherapy. Results of an observational study. *Tumori*. 2004 Jul-Aug;90(4):379-86.
16. **Gori S**, Porrozzì S, Roila F, Gatta G, De Giorni U, Marangolo M: Germ cell tumours of the testis. *Critical Review in Oncology/Hematology* 2005; 53:141-164
17. Colozza M, Sidoni A, Mosconi AM, Cavaliere A, Bisagni G, **Gori S**, De Angelis V, Frassoldati A, Cherubini R, Bian AR, Rodino C, Mazzocchi B, Mihailova Z, Bucciarelli E, Tonato M; Italian Oncology Group for Clinical Research. HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results. *Clin Breast Cancer*. 2005; 6 :253-9
18. Stracci F, La Rosa F, Falsetti E, Ricci E, Aristei C, Bellezza G, Bolis GB, Fenocchio D, **Gori S**, Rulli A, Mastrandrea V: A population survival model for breast cancer. *The Breast* 2005; 14:94-102
19. **Gori S**, Foglietta J, Crinò L: Lapatinib in breast cancer. *Supportive and Palliative Cancer Care* 2006; 3 (1) (supplement):59-62
20. Franceschi E, Scopece L, **Gori S**, Chiari R, Crino L. PRIMARY AND METASTATIC BRAIN TUMORS. *Forum (Genova)*. 2006 Jun 1;14(1):E2.
21. Cavaliere A, Scheibel M, Bellezza G, Coltella R, Vitali R, **Gori S**, Aristei C, Rulli A, Sidoni A: Ductal carcinoma in situ with microinvasion: clinicopathologic study and bipathologic profile. *Pathology Research and Practice* 2006; 202:131-135
22. **Gori S**, Rulli A, Mosconi AM, Colozza M, Crinò L : Safety of epirubicin adjuvant chemotherapy in a breast cancer patient with chronic renal failure undergoing hemodialytic treatment. *Tumori* 2006; 92: 364-365
23. Sidoni A, Cavaliere A, Bellezza G, Del Sordo R, Angiero F, **Gori S**, Rulli A, Bucciarelli E. Coexpression of HER-2/neu and p53 in breast cancer identifies a subset with an aggressive biopathological profile. *Tumori*. 2006; 92 :412-5.
24. **Gori S**, Rimondini S, De Angelis V, Colozza M, Bisagni G, Moretti G, Sidoni A, Basurto C, Aristei C, Anastasi P, Crino L. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. *Oncologist*. 2007 Jul;12(7):766-7
25. Barni S, Venturini M, Beretta GD, **Gori S**, Molino A, Carnaghi C, Labianca R, Sgarbi S, Simoni L, Maiello E: Agreement between oncology guidelines and clinical practice in Italy: the "right" program. A project of the Italian Association of Medical oncology (AIOM). *Ann Oncol* 2007; 18 (suppl 6): vi179-vi184.

26. **Gori S**, De Angelis V, Colozza M, Crinò L: In Replay to: Clinical utility of continuing Trastuzumab beyond brain progression in HER2 positive metastatic breast cancer by Metro G, Sperduti I, Russillo M, Milella M, Cognetti F, Fabi A. *Oncologist* 2007; 12:1469-71
27. Ludovini V, **Gori S**, Colozza M, Pistola L, Rulli E, Floriani I, Pacifico E, Tofanetti FR, Sidoni A, Basurto C, Rulli A, Crinò L. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. *Ann Oncol.* 2008 May;19(5):883-90.
28. Nuzzo F, Morabito A, De Maio E, Di Rella F, Gravina A, Labonia V, Landi G, Pacilio C, Piccirillo MC, Rossi E, D'Aiuto G, Thomas R, **Gori S**, Colozza M, De Placido S, Lauria R, Signoriello G, Gallo C, Perrone F, de Matteis A. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. *Crit Rev Oncol Hematol.* 2008 May;66(2):171-80.
29. Ludovini V, **Gori S**, Pistola L, Della Fazio MA, Piobbico D, Servillo G, Flacco A, Scuderi C, Crinò L. Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation. *J Thorac Oncol.* 2008 Apr;3(4):452-3
30. Sidoni A, Cartaginense F, Colozza M, **Gori S**, Crinò L: ERCC1 expression in triple negative breast carcinoma: the paradox revisited. *Breast Cancer Res Treat* 2008; 111:569-570
31. Colozza M, Minenza E, **Gori S**, Fenocchio D, Paolucci C, Aristei C, Floridi P. Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. *Cancer Chemother Pharmacol.* 2009 May;63(6):1157-9
32. **Gori S**, Silva R.R: Letrozolo nel trattamento adiuvante del carcinoma mammario: review dello studio BIG 1-98. *TUMORI*, 2009; 95:1-10
33. Antognelli C, Del Buono C, Ludovini V, **Gori S**, Talesa VN, Crinò L, Barberini F, Rulli A. CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study. *BMC Cancer.* 2009 Apr 20;9:115.
34. Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roché H, Liu MC, Greil R, Ciruelos E, Loibl S, **Gori S**, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. *Clin Cancer Res.* 2009 Feb 15;15(4):1452-9.
35. **Gori S**, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, Stocchi L, Foglietta J, Ludovini V, Minenza E, De Angelis V, Crinò L. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. *Ann Oncol.* 2009 Apr;20(4):648-54.
36. **Gori S**, Di Maio M, Pinto C, Alabiso O, Baldini E, Beretta GD, Caffo O, Caroti C, Crinò L, De Laurentiis M, Dinota A, Di Vito F, Gebbia V, Giustini L, Graiff C, Guida M, Lelli G, Lombardo M, Muggiano A, Puglisi F, Romito S, Salvagno L, Tagliaferri P, Terzoli E, Venturini M; AIOM Working Group Interaction with Regional Sections (2007-2009). Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM). *Tumori.* 2010 Nov-Dec;96(6):1010-1015.
37. Rulli A, Barberini F, Scialpi M, Izzo L, D'Angeli I, **Gori S**, Sidoni A, Rondelli F, Noya G, Aristei C. Interstitial high-dose-rate brachytherapy after breast conserving surgery. *Oncol Rep.* 2010 Aug;24(2):417-22
38. Metro G, Foglietta J, Russillo M, Stocchi L, Vidiri A, Giannarelli D, Crinò L, Papaldo P, Mottolese M, Cognetti F, Fabi A, **Gori S**. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. *Ann Oncol.* 2011 Mar;22(3):625-30.
39. Barni S, Venturini M, Molino A, Donadio M, Rizzoli S, Maiello E, **Gori S**. Importance of adherence to guidelines in breast cancer clinical practice. The Italian experience (AIOM). *Tumori.* 2011 Sep-Oct;97(5):559-63.
40. **Gori S**, Di Maio M, Pinto C, Alabiso O, Baldini E, Barbato E, Beretta GD, Bravi S, Caffo O, Canobbio L, Carrozza F, Cinieri S, Cruciani G, Dinota A, Gebbia V, Giustini L, Graiff C, Molino A, Muggiano A, Pandoli G, Puglisi F, Tagliaferri P, Tomao S, Venturini M; AIOM Working Group "Interactions with Regional Sections" (2009-2011). Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM). *Tumori.* 2011 Jul-Aug;97(4):442-8. doi: 10.1700/950.10395.
41. **Gori S**, Greco MT, Catania C, Colombo C, Apolone G, Zagonel V; AIOM Group for the Informed Consent in Medical Oncology. A new informed consent form model for cancer patients: preliminary results of a prospective study by the Italian Association of Medical Oncology (AIOM). *Patient Educ Couns.* 2012 ;87:243-9.
42. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, **Gori S**, Giordano M, Garrone O, Pronzato P, Bighin C, Levaggi A, Giraudi S, Cresti N, Magnolfi E, Scotto T, Vecchio C, Venturini M Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. *JAMA.* 2011 ;306(3):269-76.
43. Tarantini L, **Gori S**, Faggiano P, Pulignano G, Simoncini E, Tuccia F, Ceccherini R, Bovelli D, Lestuzzi C, Cioffi G; on behalf of ICARO (Italian CARdio-Oncologic) Network . Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis. *Ann Oncol.* 2012 Dec;23(12):3058-63.
44. Clavarezza M, Mustacchi G, Gardini AC, Del Mastro L, De Matteis A, Riccardi F, Adamo V, Aitini E, Amoroso D, Marchetti P, **Gori S**, Carrozza F, Maiello E, Giotto F, Dondi D, Venturini M. Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMES1 study. *BMC Cancer.* 2012 ;12:216.

45. **Gori S**, Clavarezza M, Siena S, Foglietta J, Tarenzi E, Giordano M, Molino A, Graiff C, Fusco V, Alabiso O, Baldini E, Gamucci T, Altavilla G, Dondi D, Venturini M. Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMES study. *BMC Cancer*. 2012;12:158.
46. **Gori S**, Foglietta J, Mameli MG, Stocchi L, Fenocchio D, Anastasi P, Iacono D, Del Sordo R, Basurto C, De Angelis V, Sidoni A. HER-3 status by immunohistochemistry in HER-2-positive metastatic breast cancer patients treated with trastuzumab: correlation with clinical outcome. *Tumori*. 2012 ;98(1):39-44.
47. Pestrin M, Bessi S, Puglisi F, Minisini AM, Masci G, Battelli N, Ravaioli A, Gianni L, Di Marsico R, Tondini C, **Gori S**, Coombes CR, Stebbing J, Biganzoli L, Buyse M, Di Leo A. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. *Breast Cancer Res Treat*. 2012 Jul;134(1):283-9.
48. Tarantini L, Cioffi G, **Gori S**, Tuccia F, Boccardi L, Bovelli D, Lestuzzi C, Maurea N, Oliva S, Russo G, Faggiano P; Italian Cardio-Oncologic Network. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. *J Card Fail*. 2012 Feb;18(2):113-9.
49. **Gori S**, Montemurro F, Spazzapan S, Metro G, Foglietta J, Bisagni G, Ferzi A, Silva RR, Gamucci T, Clavarezza M, Stocchi L, Fabi A, Cognetti F, Torrisi E, Crivellari D. Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. *Ann Oncol*. 2012 Jun;23(6):1436-41.
50. Tarantini G, Feola M, Albini A, **Gori S**, Foglietta J, Cicoira MA, Pulignano G. Io scompenso cardiaco da trastuzumab nel trattamento del tumore al seno. *G Ital Cardiol* 2012; 13 (5 suppl 1): 54S-62S
51. Tarantini L, Feola M, Albini A, **Gori S**, Foglietta J, Cicoira MA, Pulignano G. Heart failure in women treated with adjuvant trastuzumab for breast cancer. *G Ital Cardiol (Rome)* 2012 May;13(5 Suppl 1):54S-62S. Italian.
52. Natoli C, Vici P, Sperduti I, Grassadonia A, Bisagni G, Tinari N, Michelotti A, Zampa G, **Gori S**, Moscetti L, De Tursi M, Panebianco M, Mauri M, Ferrarini I, Pizzuti L, Ficorella C, Samaritani R, Mentuccia L, Iacobelli S, Gamucci T. Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer. *J Cancer Res Clin Oncol* 2013 Jul;139(7):1229-40.
53. **Gori S**, Di Maio M, Pinto C, Alabiso O, Baldini E, Barbato E, Beretta GD, Bravi S, Caffo O, Canobbio L, Carrozza F, Cinieri S, Cruciani G, Dinota A, Gebbia V, Giustini L, Graiff C, Molino A, Muggiano A, Pandoli G, Puglisi F, Tagliaferri P, Tomao S, Lunardi G, Venturini M; AIOM Working Group "Interaction with Regional Sections" (2009-2011). Impact of use of oral anticancer drugs on activity of Italian oncology practices: results of a survey conducted by the Italian Society of Medical Oncology (AIOM). *Tumori* 2013 Jan-Feb;99(1):35-8.
54. Fabi A, Merola R, Ferretti G, Di Benedetto A, Antoniani B, Ercolani C, Nisticò C, Papaldo P, Ciccarese M, Sperduti I, Vici P, Marino M, **Gori S**, Botti C, Malaguti P, Cognetti F, Mottolese M. Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer. *Expert Opin Pharmacother* 2013 Apr;14(6):699-706.
55. Bisagni G, Musolino A, Panebianco M, De Matteis A, Nuzzo F, Ardizzoni A, **Gori S**, Gamucci T, Passalacqua R, Gnani R, Moretti G, Boni C. The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. *Cancer Chemother Pharmacol* 2013 Apr;71(4):1051-7.
56. Tarantini L., Faggiano P., Barni S., **Gori S**. Monitoraggio del danno cardiaco nel paziente oncologico in trattamento con farmaci cardiotossici. *G Ital Cardiol* 2013 Giugno, vol 14: 416-423.
57. **Gori S**, Foglietta J, Rossi M, Hamzaj A, Stocchi L, Galuppo C, Picev V, et al. Sunitinib therapy in metastatic papillary thyroid cancer. *Tumori* 2013 Novembre; 99 (6): e285-e287.
58. Russo G, Cioffi G, **Gori S**, Tuccia F, Boccardi L, Khoury G, Lestuzzi C, Maurea N, Oliva S, Faggiano P, Tarantini L, on behalf of ICARO (Italian CARDio-Oncological) Network. Role of hypertension in new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer. *J Cardiovasc Med* 2014 Febbraio; 15 (2): 141-146.
59. **Gori S**, Lunardi G, Inno A, Foglietta J, Cardinali B, Del Mastro L, Crinò L. Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases. *Ann Oncol* 2014 Aprile; 25(4): 912-913.
60. Natoli C, Brocco D, Sperduti I, Nuzzo A, Tinari N, De Tursi M, Grassadonia A, Mazzilli L, Iacobelli S, Gamucci T, Vici P, "FOLLOW-UP" Study Group (Adamo V, Airolidi M, Amoroso D, Angelini F, Angiolini C, Angiolucci G, Ardizzioia A, Baldini E, Ballardini P, Barni S, Barone C, Battelli N, Bernardi D, Bianchetti S, Bianco N, Biglia N, Bilancia D, Biti G, Boni C, Bordonaro R, Botta M, Bretti S, Brunello A, Brunetti C, Bruno D, Bucci E, Buzzoni R, Cagossi K, Cappelletti C, Cappuzzo F, Cardillo F, Carroccio R, Cascinu S, Cavanna L, Cianchetti E, Clerico M, Contu A, Corsi D, Cortesi L, Cretella E, Crispino S, Di Lieto M, Di Lullo L, Durini E, Fabi A, Failla G, Fattorusso S, Ferraù F, Ferro A, Ficorella C, Fogazzi G, Foglietta J, Francini G, Fusco O, Gennari A, Ghiani M, Gianni L, Giordano M, Giotto F, Giuliani R, **Gori S**, Graiff C, Guameri V, Guameri D, Guglielmi F, Landriscina M, Laudadio L, Lombardo M, Longo F, Macellari G, Madeddu C, Magnanini S, Maiorino L, Mangiameli A, Marini G, Massidda B, Mattioli R, Michelotti A, Molino A, Montesarchio V, Morale A, Murgo R, Naso G, Natale D, Orditura M, Orrù S, Pace R, Palazzo A, Palma F, Pancotti A, Pandoli G, Papaldo P, Parisi AM, Passalacqua R, Pellegrino A, Perrucci B, Proietti E, Recchia F, Riccardi F, Rispoli AI, Rocca A, Romaniello I, Rossetti R, Rossi D, Rosti G, Ruggeri EM, Russo A, Savarino A, Savastano C, Scognamiglio G, Scognamiglio M, Seminara P, Serrachini S, Sidoti V, Silva RR, Surace G, Tomao S, Tonini G, Trenta P, Turazza M, Valenza R, Veltri E, Zampa

- G, Zaniboni A, Zanirato S). Breast Cancer "Tailored Follow-up" in Italian Oncology Units: a web-based survey. PLoS One 2014 Aprile; 9(4): e94063.
61. De Fiore L, Costantini A, Di Maio M, **Gori S**, Lorusso D, Rosti G, Pinto C. Cancer on the big screen. How and when movies deal with oncological diseases. *Recenti Prog Med* 2014 Maggio; 105 (5): 198-209.
62. Cirillo M, Lunardi G, Coati F, Ciccarelli L, Alestra S, Mariotto M, Micheloni B, Cassandrini PA, Inno A, Magarotto R, Nicodemo M, Picece V, Turazza M, **Gori S**, Venturini M. Management of oral anticancer drugs: feasibility and patient approval of a specific monitoring program. *Tumori* 2014 Maggio-Giugno; 100 (3): 243-248.
63. Cardinali B, Lunardi G, Millo E, Amirotti A, Damonte G, Profumo A, **Gori S**, Iacono G, Levaggi A, Del Mastro L. Trastuzumab quantification in serum: a new, rapid, robust ELISA assay based on a mimetic peptide that specifically recognizes trastuzumab. *Anal Bioanal Chem* 2014 Luglio; 406 (18):4557-4561.
64. Numico G, Pinto C, **Gori S**, Ucci G, Di Maio M, Cancian M, De Lorenzo F, Silvestris N. Clinical and organizational issues in the management of surviving breast and colorectal cancer patients: attitudes and feelings of medical oncologists. *PLoS One* 2014 Luglio; 9 (7): e101170.
65. Collovà E, Ferzi A, Scandurra G, Aurilio G, Torri V, Porcu L, Sanò MV, Taibi E, Foglietta J, Generali D, Andreis D, Dazzani MC, Bramati A, Marcon I, Atzori F, Cinieri S, Tondulli L, Grasso D, Nolè F, Petrella MC, **Gori S**, La Verde N. Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis. *Tumori* 2014 Luglio-Agosto; 100(4): 426-431.
66. Puglisi F, Fontanella C, Numico G, Sini V, Evangelista L, Monetti F, **Gori S**, Del Mastro L. Follow-up of patients with early breast cancer: Is it timeto rewrite the story? *Crit Rev Oncol Hematol* 2014 Agosto; 91 (2): 130-141.
67. Alongi F, Ricchetti F, Fiorentino A, **Gori S**. Postoperative breast radiotherapy after neoadjuvant chemotherapy: which uncertainties still remain? *Tumori* 2014 Settembre-Ottobre; 100(5): 212e-213e.
68. **Gori S**, Lunardi G, Inno A, Magarotto R, Duranti S, Messa MG, Mucchino C, Cirillo M. Pharmacokinetics of oxaliplatin in a haemodialyzed patient: chemotherapy dose adjustment and timing of dialysis. *Clinical Colorectal cancer* 2014 Dicembre; 13(4): 260-263.
69. Inno A, Fanetti G, Di Bartolomeo M, **Gori S**, Maggi C, Cirillo M, Iacovelli R, Nichetti F, Martinetti A, de Braud F, Bossi I, Pietrantonio F. Role of MGMT as biomarker in colorectal cancer. *World Journal of Clinical Cases* 2014 Dicembre; 2(12): 835-839.
70. Alongi F, Mazzola R, Ricchetti F, Fersino S, Levra N, Fiorentino A, Naccarato S, Sicignano G, Di Paola G, Ruggieri R, **Gori S**, Ceccaroni M. Volumetric-modulated arc therapy with vaginal cuff simultaneous integrated boost as an alternative to brachytherapy in adjuvant irradiation for endometrial cancer: a prospective study. *Anticancer Res.* 2015 Apr;35(4):2149-55.
71. Bogina G, Lunardi G, Coati F, Zamboni G, **Gori S**, Bortesi L, Marconi M, Cassandrini P, Turazza M, Cortesi L, DeMatteis E, Ficarra G, Ibrahim T, Serra P, Medri L, Giraudi S, Lambertini M, Carli F, Foglietta J, Sidoni A, Nunzi M, Ficorella C, Diadema M, Del Mastro L. Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence. *Tumori.* 2015 Aug;101(4):398-403.
72. Fiorentino A, Mazzola R, Ricchetti F, Gaj Levra N, Fersino S, Naccarato S, Sicignano G, Ruggieri R, Di Paola G, Massocco A, **Gori S**, Alongi F. Intensity modulated radiation therapy with simultaneous integrated boost in early breast cancer irradiation. Report of feasibility and preliminary toxicity. *Cancer Radiother.* 2015 Aug;19(5):289-94.
73. Foglietta J, Metro G, Crinò L, **Gori S**. Letter to the editor concerning 'Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA'. *Ann Oncol.* 2015 May;26(5):1033-4.
74. **Gori S**, Foglietta J, Lunardi G, Inno A, Cardinali B, Millo E, Del Mastro L, Nunzi E, Crinò L. Pharmacokinetics of trastuzumab in haemodialysis. *Breast J.* 2015 Jun;21(3):329-31.
75. **Gori S**, Inno A, Fiorio E, Foglietta J, Ferro A, Gulisano M, Pinotti G, Gubiotti M, Cavazzini M, Turazza M, Duranti S, De Simone V, Iezzi L, Bisagni G, Spazzapan S, Cavanna L, Saggia C, Bria E, Cretella E, Vici P, Santini D, Fabi A, Garrone O, Frassoldati A, Amaducci L, Saracchini S, Evangelisti L, Barni S, Gamucci T, Mentuccia L, Laudadio L, Zoboli A, Marchetti F, Bogina G, Lunardi G, Boni L. Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. *PLoS One* [Internet]. 2015 Sep 25 [cited 2016 Oct 1];10(9). Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583491/>
76. **Gori S**, Inno A, Fiorio E, Foglietta J, Ferro A, Gulisano M, Pinotti G, Gubiotti M, Cavazzini M, Turazza M, Duranti S, De Simone V, Iezzi L, Bisagni G, Spazzapan S, Cavanna L, Saggia C, Bria E, Cretella E, Vici P, Santini D, Fabi A, Garrone O, Frassoldati A, Amaducci L, Saracchini S, Evangelisti L, Barni S, Gamucci T, Mentuccia L, Laudadio L, Zoboli A, Marchetti F, Bogina G, Lunardi G, Boni L. The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. *PLoS ONE.* 2015;10(9):e0136731.
77. **Gori S**, Inno A, Lunardi G, Gorgoni G, Malfatti V, Severi F, Alongi F, Carbognin G, Romano L, Pasetto S, Salgarello M. 18F-Sodium Fluoride PET-CT for the Assessment of Brain Metastasis from Lung Adenocarcinoma. *J Thorac Oncol.* 2015 Aug;10(8):e67-68.
78. Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, **Gori S**, Giordano M, Garrone O, Levaggi A, Poggio F, Giraudi S, Bighin C, Vecchio C, Sertoli M, Pronzato P, Del Mastro L, GIM Study Group. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial. *JAMA.* 2015 Dec 22;314(24):2632-40.

79. Metro G, Chiari R, Ricciuti B, Rebonato A, Lupattelli M, **Gori S**, Bennati C, Castrioto C, Floridi P, Minotti V, Chiarini P, Crinò L. Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. *Expert Opin Pharmacother*. 2015;16(17):2601–13.
80. Metro G, Lunardi G, Floridi P, Pascali J, Marcomigni L, Chiari R, Ludovini V, Crinò L, **Gori S**. CSF Concentration of Crizotinib in Two ALK-Positive Non-Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment. *J Thorac Oncol*. 2015 May;10(5):e26-27.
81. Perrone F, Nuzzo F, Di Rella F, Gravina A, Iodice G, Labonia V, Landi G, Pacilio C, Rossi E, De Laurentiis M, D'Aiuto M, Botti G, Forestieri V, Lauria R, De Placido S, Tinessa V, Daniele B, **Gori S**, Colantuoni G, Barni S, Riccardi F, De Maio E, Montanino A, Morabito A, Daniele G, Di Maio M, Piccirillo M, Signoriello S, Gallo C, de Matteis A. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. *Ann Oncol*. 2015 Apr;26(4):675–82.
82. Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, **Gori S**, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby R, Semiglazov V. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. *J Clin Oncol*. 2015 May 10;33(14):1564–73.
83. Tinari N, Fanizza C, Romero M, Gambale E, Moscetti L, Vaccaro A, Seminara P, Longo F, **Gori S**, Vici P, Gamucci T, Mauri M, Laudadio L, Nuzzo A, Fabbri M, Fattoruso S, Mazzilli L, Grassadonia A, Cianchetti E, Natoli C. Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian survey. *Clin Breast Cancer*. 2015 Apr;15(2):e131-137.
84. Aurilio G, **Gori S**, Nolè F, Pruneri G, Coati F, Torri V, Lunardi G, Atzori F, La Verde N, Banna G, Rossi A, Del Mastro L, Di Fabio F, Marcon I, Gebbia V, Loupakis F, Orlando L, Ciuffreda L, Amadio P, Luppi G, Redana S, Filippelli G, Gentile A, Collovà E. Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology. *Tumori*. 2016 Feb;102(1):108–13.
85. Bogina G, Munari E, Brunelli M, Bortesi L, Marconi M, Sommaggio M, Lunardi G, **Gori S**, Massocco A, Pegoraro M, Zamboni G. Neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome. *Histopathology*. 2016 Feb;68(3):422–32.
86. Cirillo M, Carlucci L, Pacchetti I, Rulli E, Sacco C, Zagonel V, Baldini E, Rojas Llimpe F, Tonini G, Leo S, Meacci M, Tartarone A, Tortora G, Zaninelli M, Valori V, Quaranta A, Cretella E, Lunardi G, Pinto C, **Gori S**. Oral Anticancer Therapy Project: clinical utility of a specific home care nursing program. *J Clin Oncol [Internet]*. 2016 [cited 2016 Nov 16];34(suppl; abstr 6597). Available from: <http://meetinglibrary.asco.org/content/166764-176>
87. Gobbi F, Buonfrate D, Menegon M, Lunardi G, Angheben A, Severini C, **Gori S**, Bisoffi Z. Failure of dihydroartemisinin-piperaquine treatment of uncomplicated Plasmodium falciparum malaria in a traveller coming from Ethiopia. *Malar J*. 2016 Nov 3;15(1):525.
88. **Gori S**, Inno A, Rossi V, Turazza M, Fiorio E, Fabi A, Bisagni G, Foglietta J, Santini D, Pavese I, Pellegrino A, Zambelli A, Vici P, Leonardi V, Barni S, Saracchini S, Bogina G, Marchetti F, Duranti S, Lunardi G, Montemurro F. Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study. *PLoS ONE*. 2016;11(5):e0156221.
89. Inno A, Bogina G, Turazza M, Bortesi L, Duranti S, Massocco A, Zamboni G, Carbognin G, Alongi F, Salgarello M, **Gori S**. Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives. *Oncologist*. 2016 Jan;21(1):28–32.
90. Mazzola R, Ricchetti F, Fersino S, Giaj Levra N, Fiorentino A, Nicodemo M, Albanese S, **Gori S**, Alongi F. Effectiveness of tapentadol prolonged release for the management of painful mucositis in head and neck cancers during intensity modulated radiation therapy. *Support Care Cancer*. 2016 Oct;24(10):4451–5.
91. Metro G, Lunardi G, Bennati C, Chiarini P, Sperduti I, Ricciuti B, Marcomigni L, Costa C, Crinò L, Floridi P, **Gori S**, Chiari R. Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series. *J Neurooncol*. 2016 Sep;129(2):355–61.
92. Pinto C, Bella M, Capoluongo E, Carrera P, Clemente C, Colombo N, Cortesi L, De Rosa G, Fenizia F, Genuardi M, **Gori S**, Guameri V, Marchetti A, Marchetti P, Normanno N, Pasini B, Pignata S, Radice P, Ricevuto E, Russo A, Tagliaferri P, Tassone P, Truini M, Varesco L. Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. *Future Oncol*. 2016 Sep;12(18):2071–5.
93. Salgarello M, Lunardi G, Inno A, Pasetto S, Severi F, Gorgoni G, **Gori S**. 18F-NaF PET/CT Imaging of Brain Metastases. *Clin Nucl Med*. 2016 Jul;41(7):564–5.
94. Vici P, Pizzuti L, Sperduti I, Frassoldati A, Natoli C, Gamucci T, Tomao S, Michelotti A, Moscetti L, **Gori S**, Baldini E, Giotto F, Cassano A, Santini D, Giannarelli D, Di Lauro L, Corsi D, Marchetti P, Sini V, Sergi D, Barba M, Maugeri-Saccà M, Russillo M, Mentuccia L, D'Onofrio L, Iezzi L, Scinto A, Da Ros L, Bertolini I, Basile M, Rossi V, De Maria R, Montemurro F. 'Triple positive' early breast cancer: an observational multicenter retrospective analysis of outcome. *Oncotarget*. 2016 Apr 5;7(14):17932–44.
95. Zagonel V, Torta R, Franciosi V, Brunello A, Biasco G, Cattaneo D, Cavanna L, Corsi D, Farina G, Fioretto L, Gamucci T, Lanzetta G, Magarotto R, Maltori M, Mastromauro C, Melotti B, Meriggi F, Pavese I, Piva E, Sacco C, Tonini G, Trentin L, Ermacora P, Varetto A, Merlin F, **Gori S**, Cascinu S, Pinto C, AIOM Simultaneous & Continuous Care (SCC) Task Force - ESMO - DCs. Early Integration of Palliative Care in Oncology Practice: Results of the Italian Association of Medical Oncology (AIOM) Survey. *Journal of Cancer*. 2016 Sep;7(14):1968–78

96. Inno A, Di Noia V, D'Argento E, Modena A, **Gori S**. State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer. *Transl Lung Cancer Res*. 2016 Dec;5(6):599–609.
97. **Gori S**, Pinto C, Caminiti C, Aprile G, Marchetti P, Perrone F, Di Maio M, Omodeo Salè E, Mancuso A, De Cicco M, Di Costanzo F, Crispino S, Passalacqua R, Merlano M, Zagonel V, Fioretto L, Micallo G, Labianca R, Bordonaro R, Comandone A, Spinsanti S, Iacono C, Nicolis F. Ethics in oncology: principles and responsibilities declared in the Italian Ragusa statement. *Tumori*. 2016 Dec 1;102(6):e25–7.
98. Zagonel V, Franciosi V, Brunello A, Biasco G, Brogna C, Cattaneo D, Cavanna L, Corsi D, Farina G, Fioretto L, Gamucci T, Lanzetta G, Magarotto R, Maltoni M, Marchetti P, Massa E, Mastromauro C, Melotti B, Meriggi F, Nacci A, Pavese I, Piva E, Quirino M, Roselli M, Sacco C, Tonini G, Trentin L, Ucci G, Labianca R, **Gori S**, Pinto C, Cascinu S, AIOM Simultaneous and Continuous Care (SCC), Task Force: ESMO Italian DCs. Position paper of the Italian Association of Medical Oncology on early palliative care in oncology practice (Simultaneous Care). *Tumori*. 2017 Jan 21;103(1):9–14.
99. Foglietta J, Inno A, de Iulio F, Sini V, Duranti S, Turazza M, Tarantini L, **Gori S**. Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients. *Clin Breast Cancer*. 2017 Feb;17(1):11–7.
100. Del Re M, Tiseo M, Bordi P, D'Incecco A, Camerini A, Petrini I, Lucchesi M, Inno A, Spada D, Vasile E, Citi V, Malpeli G, Testa E, **Gori S**, Falcone A, Amoroso D, Chella A, Cappuzzo F, Ardizzoni A, Scarpa A, Danesi R. Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. *Oncotarget*. 2017 Feb 21;8(8):13611–9.
101. Alongi F, Fersino S, Mazzola R, Fiorentino A, Gaj-Levra N, Ricchetti F, Ruggieri R, Di Paola G, Cirillo M, **Gori S**, Salgarello M, Zamboni G, Ruffo G. Radiation dose intensification in pre-operative chemo-radiotherapy for locally advanced rectal cancer. *Clin Transl Oncol*. 2017 Feb;19(2):189–96.
102. **Gori S**, Zagonel V. Author's reply to: Patient-centered medicine in palliative cancer care: the impossible choice between physician's responsibility and patient's preferences. *Tumori*. 2017 Mar 24;103(2):e22.
103. Mazzola R, Ricchetti F, Fiorentino A, Gaj-Levra N, Fersino S, Tebano U, Albanese S, **Gori S**, Alongi F. Fentanyl pectin nasal spray for painful mucositis in head and neck cancers during intensity-modulated radiation therapy with or without chemotherapy. *Clin Transl Oncol*. 2017 May;19(5): 593–8.
104. Calegari MA, Inno A, Monterisi S, Orlandi A, Santini D, Basso M, Cassano A, Martini M, Cenci T, de Pascalis I, Camarda F, Barbaro B, Larocca LM, **Gori S**, Tonini G, Barone C. A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. *Br J Cancer*. 2017 May 9;116(10):1279–86.
105. Sini V, Botticelli A, Lunardi G, **Gori S**, Marchetti P. Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients. *Pharmacogenomics*. 2017 Jun;18(8):821–30.
106. Ludovini V, Antognelli C, Rulli A, Foglietta J, Pistola L, Eliana R, Floriani I, Nocentini G, Tofanetti FR, Piattoni S, Minenza E, Talesa VN, Sidoni A, Tonato M, Crinò L, **Gori S**. Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy. *BMC Cancer*. 2017 Jul 26;17(1):502.
107. Muscaritoli M, Lucia S, Farcomeni A, Lorusso V, Saracino V, Barone C, Plastino F, **Gori S**, Magarotto R, Carteni G, Chirazzi B, Pavese I, Marchetti L, Zagonel V, Bergo E, Tonini G, Imperatori M, Iacono C, Maiorana L, Pinto C, Rubino D, Cavanna L, Cicilia RD, Gamucci T, Quadrini S, Palazzo S, Minardi S, Merlano M, Colucci G, Marchetti PM, on behalf of the PreMiO Study Group. Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study. *Oncotarget*. 2017 Aug 11;8(45):79884–96.
108. Inno A, Metro G, Bironzo P, Grimaldi AM, Grego E, Di Nunno V, Picasso V, Massari F, **Gori S**. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. *Tumori*. 2017 Sep 18;103(5):405–21.
109. Cinefra M, Cagnazzo C, McMahon L, Arizio F, Campora S, Camisa R, Canzanella G, Contu M, Frati P, Sottile R, **Gori S**, Procopio G, Nanni O. The critical role of the clinical research coordinator for clinical trials: a survey in oncology. *Med Access @ point care* [Internet]. 2017 Oct 5 [cited 2018 Jan 11];1(1).
110. Sbardella E, Isidori AM, Arnaldi G, Arosio M, Barone C, Benso A, Berardi R, Capasso G, Caprio M, Ceccato F, Corona G, Della Casa S, De Nicola L, Faustini-Fustini M, Fiaccadori E, Gesualdo L, **Gori S**, Lania A, Mantovani G, Menè P, Parenti G, Pinto C, Pivonello R, Razzore P, Regolisti G, Scaroni C, Trepiccione F, Lenzi A, Peri A, the: Fluid and Electrolyte Disorders Club of the Italian Society of Endocrinology; Italian Society of Nephrology; and Italian Association of Medical Oncology. Approach to hyponatremia according to the clinical setting: Consensus statement from the Italian Society of Endocrinology (SIE), Italian Society of Nephrology (SIN), and Italian Association of Medical Oncology (AIOM). *J Endocrinol Invest*. 2018 Jan;41(1):3–19.
111. Ghelfi F, Tieri M, **Gori S**, Nicolis F, Petrella MC, Filiberti A, Apolone G, Titta L. Do cancer patients change their diet in the e-health information era? A review of the literature and a survey as a proposal for the Italian population. *Food Res Int*. 2018 Feb;104:59–68.
112. Dieci MV, Guameri V, Giarratano T, Mion M, Tortora G, De Rossi C, **Gori S**, Oliani C, Merlini L, Pasini F, Bonciarelli G, Griguolo G, Orvieto E, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte P. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer. *Oncologist*. 2018 Mar;23(3):297–305.
113. Inno A, Lo Russo G, Salgarello M, Corrao G, Casolino R, Galli G, Modena A, Romano L, Pusceddu S, Greco FG, Garassino MC, **Gori S**. The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST. *Tumori*. 2018 Mar 1;
114. Crocetti E, **Gori S**, Falcini F. Metastatic breast cancers: Estimates for Italy. *Tumori*. 2018 Apr;104(2):116–20.

115. De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, **Gori S**, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F, GIM Investigators. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. *Lancet Oncol.* 2018 Apr;19(4):474–85.
116. Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, Cucchi G, Menatti E, Mangiavacchi M, Cavina R, Barbieri E, **Gori S**, Colombo A, Curigliano G, Salvatici M, Rizzo A, Ghisoni F, Bianchi A, Falci C, Aquilina M, Rocca A, Monopoli A, Milandri C, Rossetti G, Bregni M, Sicuro M, Malossi A, Nassiacos D, Verusio C, Giordano M, Staszewsky L, Barlera S, Nicolis EB, Magnoli M, Masson S, Cipolla CM, ICOS-ONE Study Investigators. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. *Eur J Cancer.* 2018 May;94:126–37.
117. Fiorentino A, Mazzola R, Giaj Levra N, Fersino S, Ricchetti F, Di Paola G, **Gori S**, Massocco A, Alongi F. Comorbidities and intensity-modulated radiotherapy with simultaneous integrated boost in elderly breast cancer patients. *Aging Clin Exp Res.* 2018 May;30(5):533–8.
118. Mantovani A, Bonapace S, Lunardi G, Salgarello M, Dugo C, Canali G, Byrne CD, **Gori S**, Barbieri E, Targher G. Association between plasma ceramides and inducible myocardial ischemia in patients with established or suspected coronary artery disease undergoing myocardial perfusion scintigraphy. *Metab Clin Exp.* 2018 May 16;
119. Pinto C, Normanno N, Orlandi A, Fenizia F, Damato A, Maiello E, Tamburini E, Di Costanzo F, Tonini G, Bilancia D, Corsi D, Piscanti S, Ferrau F, **Gori S**, Daniele B, Zaniboni A, Soto Parra H, Frassinetti GL, Iaffaioli RV, Cassata A, Zampino MG, Repetto L, Calegari MA, Barone C, all the investigators of ERMES study group. Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC. *Future Oncol.* 2018 Jun;14(14):1339–46.
120. **Gori S**, Puglisi F, Cinquini M, Pappagallo G, Frassoldati A, Biganzoli L, Cortesi L, Fiorentino A, Angiolini C, Tinterri C, De Censi A, Levaggi A, Del Mastro L. Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM). *Eur J Cancer.* 2018 Jun 7;99:9–19.
121. **Gori S**, Turazza M, Modena A, Duranti S, Zamboni G, Alongi F, Carbognin G, Massocco A, Salgarello M, Inno A. When and how to treat women with HER2-positive, small (pT1a-b), node-negative breast cancer? *Crit Rev Oncol Hematol.* 2018 Aug;128:130–8.
122. Roila F, Fumi G, Ruggeri B, Antonuzzo A, Ripamonti C, Fatigoni S, Cavanna L, **Gori S**, Fabi A, Marzano N, Graiff C, De Sanctis V, Mirabile A, Serpentine S, Bocci C, Pino MS, Cilenti G, Verusio C, Ballatori E, NCSO (Network Italiano per le Cure di Supporto in Oncologia). Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NCSO). *Support Care Cancer.* 2018 Aug 6;
123. Pelizzari G, Arpino G, Biganzoli L, Cinieri S, De Laurentiis M, Del Mastro L, Di Leo A, **Gori S**, Guameri V, Marchetti P, Puglisi F. An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. *BMC Cancer.* 2018 Sep 27;18(1):932.
124. Mantovani A, Bonapace S, Lunardi G, Salgarello M, Dugo C, **Gori S**, Barbieri E, Verlati G, Laaksonen R, Byrne CD, Targher G. Association of Plasma Ceramides With Myocardial Perfusion in Patients With Coronary Artery Disease Undergoing Stress Myocardial Perfusion Scintigraphy. *Arterioscler Thromb Vasc Biol.* 2018 Dec;38(12):2854–61.
125. Zambetti M, Montemurro F, Morandi P, Zamagni C, Brandes AA, Bisagni G, Cagossi K, Bengala C, **Gori S**, Iannaccone C, Stell A, Gianni L. Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study. *Eur J Cancer.* 2018 Dec;105:61–70.
126. Roila F, Fumi G, Ruggeri B, Antonuzzo A, Ripamonti C, Fatigoni S, Cavanna L, **Gori S**, Fabi A, Marzano N, Graiff C, De Sanctis V, Mirabile A, Serpentine S, Bocci C, Pino MS, Cilenti G, Verusio C, Ballatori E, NCSO (Network Italiano per le Cure di Supporto in Oncologia). Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NCSO). *Support Care Cancer.* 2019 Mar;27(3):1041–7.
127. Vermieri C, Galli F, Ferrari L, Marchetti P, Lonardi S, Maiello E, Iaffaioli RV, Zampino MG, Zaniboni A, De Placido S, Banzi M, Damiani A, Ferrari D, Rosati G, Labianca RF, Bidoli P, Frassinetti GL, Nicolini M, Pavesi L, Tronconi MC, Buonadonna A, Ferrario S, Re GL, Adamo V, Tamburini E, Clerico M, Giordani P, Leonardi F, Barni S, Ciarlo A, Cavanna L, **Gori S**, Cinieri S, Faedi M, Aglietta M, Antista M, Dotti KF, Galli F, Di Bartolomeo M, TOSCA (Three or Six Colon Adjuvant) Investigators. Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. *Oncologist.* 2019 Mar;24(3):385–93.
128. Mazzola R, Corradini S, Eidemüller M, Figlia V, Fiorentino A, Giaj-Levra N, Nicosia L, Ricchetti F, Rigo M, Musola M, Ceccaroni M, **Gori S**, Magrini SM, Alongi F. Modern radiotherapy in cancer treatment during pregnancy. *Crit Rev Oncol Hematol.* 2019 Apr;136:13–9.

129. **Gori S**, Barberis M, Bella MA, Buttitta F, Capoluongo E, Carrera P, Colombo N, Cortesi L, Genuardi M, Gion M, Guarneri V, Incorvaia L, La Verde N, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group. Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. *Crit Rev Oncol Hematol*. 2019 May 25;140:67–72.
130. Apolone G, Ardizzoni A, Buzzetti G, Clerico MA, Conte P, de Braud F, De Lorenzo F, Ferrandina MG, Genazzani A, **Gori S**, Maio M, Patroncini M, Perrone F, Scambia G, Scroccaro G. Early Access in Oncology: Why Is It Needed? Global & Regional Health Technology Assessment. 2019 Jun.
131. Galvano A, Guarini A, Iacono F, Castiglia M, Rizzo S, Tarantini L, **Gori S**, Novo G, Bazan V, Russo A. An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy. *Expert Opin Drug Saf*. 2019 Jun;18(6):485–96.
132. Pasello G, Vicario G, Zustovich F, Oniga F, **Gori S**, Rosetti F, Bonetti A, Favaretto A, Toso S, Redelotti R, Santo A, Bernardi D, Giovanis P, Oliani C, Calvetti L, Gatti C, Palazzolo G, Baretta Z, Bortolami A, Bonanno L, Basso M, Menis J, Corte DD, Frega S, Guarneri V, Conte P, Veneto Oncology Network. From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study). *Oncologist*. 2019 Jun;24(6):e318–26.
133. Di Cosimo S, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Peña L de la, Daidone MG, Huober J, **Gori S**, Cinieri S, Torri V, Baselga J, Piccart M, de Braud FG, Apolone G, Verderio P, Tagliabue E. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. *Eur J Cancer*. 2019 Jul;118:1–9.
134. Vitale MG, Bracarda S, Cosmai L, Crocetti E, Di Lorenzo G, Lapini A, Mandressi A, Martorana G, Masini C, Montironi R, Ortega C, Passalacqua R, Porta C, Procopio G, Sepe P, Romano L, Luigi Pappagallo G, Conti G, Guida M, Martignoni G, Nolè F, Pignata S, **Gori S**, Carteni G. Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). *Tumori J*. 2019 Jul;105(4_suppl):3–12.
135. Galvano A, Scaturro D, Badalamenti G, Incorvaia L, Rizzo S, Castellana L, Cusenza S, Cutaia S, Santini D, Guadagni F, Roselli M, **Gori S**, Latteri MA, Bazan V, Giulia LM, Russo A. Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials. *J Bone Oncol*. 2019 Jul 16;18:100252.
136. **Gori S**, Puglisi F, Moroso S, Fabi A, La Verde N, Frassoldati A, Tarenzi E, Garrone O, Vici P, Laudadio L, Cretella E, Turazza M, Foglietta J, Leonardi V, Cavanna L, Barni S, Galanti D, Russo A, Marchetti F, Valerio M, Lunardi G, Alongi F, Inno A. The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer. *Clin Breast Cancer*. 2019 Aug;19(4):e501–e510.
137. Dieci MV, Del Mastro L, Cinquini M, Montemurro F, Biganzoli L, Cortesi L, Zambelli A, Criscitiello C, Levaggi A, Conte B, Calabrese M, Fiorentino A, Marchiò C, Tinteri C, Fittipaldo VA, Pappagallo G, **Gori S**. Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM). *Cancers (Basel)*. 2019 Aug 8;11(8).
138. Perrone F, De Laurentis M, De Placido S, Orditura M, Cinieri S, Riccardi F, Ribocco AS, Putzu C, Del Mastro L, Rossi E, Tinessa V, Mosconi AM, Nuzzo F, Di Rella F, Gravina A, Iodice G, Landi G, Pacilio C, Forestieri V, Lauria R, Fabbri A, Ibrahim T, De Maio E, Barni S, **Gori S**, Simeon V, Arenare L, Daniele G, Piccirillo MC, Normanno N, de Matteis A, Gallo C. Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBEO phase 3 randomised trial. *Eur J Cancer*. 2019 Sep;118:178–186.
139. Berardi R, Mastroianni C, Lo Russo G, Buosi R, Santini D, Montanino A, Camaghi C, Tiseo M, Chiari R, Camerini A, Barni S, De Marino V, Ferrari D, Cristofano A, Doni L, Freddari F, Fumagalli D, Portalone L, Sarmiento R, Schinzari G, Sperandi F, Tucci M, Inno A, Ciuffreda L, Mariotti M, Mariani C, Caramanti M, Torniai M, Gallucci R, Bennati C, Bordi P, Buffoni L, Galeassi A, Ghidini M, Grossi E, Morabito A, Vincenzi B, Arvat E. Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study. *Ther Adv Med Oncol*. 2019 Sep;11:175883591987772.
140. Capoluongo E, La Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, **Gori S**. BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories. *Diagnostics (Basel)*. 2019 Oct 9;9(4).
141. Capoluongo E, La Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, **Gori S**. BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories. *Diagnostics (Basel)*. 2019 Oct 9;9(4).
142. Incorvaia L, Fanale D, Badalamenti G, Barraco N, Bono M, Corsini LR, Galvano A, Gristina V, Listi A, Vieni S, **Gori S**, Bazan V, Russo A. Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). *Adv Ther*. 2019 Oct;36(10):2600–2617.
143. **Gori S**, Inno A, Belluomini L, Bocus P, Bisoffi Z, Russo A, Arcaro G. Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy. *Crit Rev Oncol Hematol*. 2019 Nov;143:139–147.

144. Dieci MV, Guarneri V, Zustovich F, Mion M, Morandi P, Bria E, Merlini L, Bullian P, Oliani C, **Gori S**, Giaratano T, Orvieto E, Griguolo G, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte P, Veneto Oncology Network. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study. *Oncologist*. 2019 Nov;24(11):1424-1431
145. Cortellini A., Tiseo M., Banna G.L., Cappuzzo F., Aerts J.G.J.V., Barbieri F., Giusti R., Bria E., Cortinovis D., Grossi F., Migliorino M.R., Galetta D., Passiglia F., Santini D., Berardi R., Morabito A., Genova C., Mazzoni F., Di Noia V., Signorelli D., Tuzi A., Gelibter A., Marchetti P., Macerelli M., Rastelli F., Chiari R., Rocco D., **Gori S**, De Tursi M., Mansueto G., Zoratto F., Santoni M., Tudini M., Rijavec E., Filetti M., Catino A., Pizzutillo P., Sala L., Citarella F., Marco R., Tomiai M., Cantini L., Targato G., Sforza V., Nigro O., Ferrara M.G., D'Argento E., Buti S., Bordini P., Antonuzzo L., Scodes S., Landi L., Guaitoli G., Baldessari C., Della Grava L., Dal Bello M.G., Belderbos R.A., Bironzo P., Carnio S., Ricciardi S., Grieco A., De Toma A., Proto C., Friedlaender A., Cantale O., Ricciuti B., Addeo A., Metro G., Ficorella C., Porzio G. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$ *Cancer Immunology, Immunotherapy* 2020, Nov;69(11):2209-2221.
146. Galvano A., Castiglia M., Rizzo S., Silvestris N., Brunetti O., Vaccaro G., Gristina V., Barraco N., Bono M., Guercio G., Graceffa G., Fulfaro F., **Gori S**, Bazan V., Russo A. Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis. *Cancer (Basel)*. 2020 Feb 26;12(3):534.
147. Pietrantonio F., Lobefaro R., Antista M., Lonardi S., Raimondi A., Morano F., Mosconi S., Rimassa L., Murgioni S., Sartore-Bianchi A., Tomasello G., Longarini R., Farina G., Petrelli F., **Gori S**, Randon G., Corallo S., Pagani F., Guarini V., Palermo F., Martinetti A., Macagno M., Barault L., Perrone F., Tamborini E., Milione M., Nicolantonio F.D., Maio M.D., Fuca G., Bartolomeo M.D., de Braud F. Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer *Clinical Cancer Research* 2020 Mar 1;26(5):1017-1024.
148. Cortellini A., Friedlaender A., Banna G.L., Porzio G., Bersanelli M., Cappuzzo F., Aerts J.G.J.V., Giusti R., Bria E., Cortinovis D., Grossi F., Migliorino M.R., Galetta D., Passiglia F., Berardi R., Mazzoni F., Di Noia V., Signorelli D., Tuzi A., Gelibter A., Marchetti P., Macerelli M., Rastelli F., Chiari R., Rocco D., Inno A., Di Marino P., Mansueto G., Zoratto F., Santoni M., Tudini M., Ghidini M., Filetti M., Catino A., Pizzutillo P., Sala L., Occhipinti M.A., Citarella F., Marco R., Tomiai M., Cantini L., Follador A., Sforza V., Nigro O., Ferrara M.G., D'Argento E., Leonetti A., Pettroruti L., Antonuzzo L., Scodes S., Landi L., Guaitoli G., Baldessari C., Bertolini F., Della Grava L., Dal Bello M.G., Belderbos R.A., De Filippis M., Cecchi C., Ricciardi S., Donisi C., De Toma A., Proto C., Addeo A., Cantale O., Ricciuti B., Genova C., Morabito A., Santini D., Ficorella C., Cannita K. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes *Clinical Lung Cancer* 2020
149. Silvestris N., Argentieri A., Beretta G.D., Di Bartolo P., Montagnani M., Danesi R., Ferrari P., D'Oronzo S., **Gori S**, Russo A., Acquati S., Gallo M. Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper. *Critical Reviews in Oncology/Hematology* 2020 Oct;154:103066.
150. Gallo M., Clemente G., Cristiano Corsi D., Michelini M., Suraci C., Farci D., Chantal Ponziani M., Candido R., Russo A., Musacchio N., Pinto C., Mannino D., **Gori S**. An integrated care pathway for cancer patients with diabetes: A proposal from the Italian experience. *Diabetes Research and Clinical Practice* 2020 Jan;159:107721.
151. Meessen J.M.T.A., Cardinale D., Ciceri F., Sandri M.T., Civelli M., Bottazzi B., Cucchi G., Menatti E., Mangiavacchi M., Condorelli G., Barbieri E., **Gori S**, Colombo A., Curigliano G., Salvatici M., Pastori P., Ghisoni F., Bianchi A., Falci C., Cortesi P., Farolfi A., Monopoli A., Milandri C., Bregni M., Malossi A., Nassiaco D., Verusio C., Staszewsky L., Leone R., Novelli D., Balconi G., Nicolis E.B., Franzosi M.G., Masson S., Garlanda C., Mantovani A., Cipolla C.M., Latini R. Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial. *ESC Heart Failure* 2020 Aug;7(4):1452-1466.
152. Combi-TED: a new trial testing Tedopi® with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line. Landi L., Delmonte A, Bonetti A, Pasello G, Metro G, Mazzoni F, Borra G, Giannarelli D, Andrikou K, Mangiola D, **Gori S**, D'Andrea MR, Minuti G, Resuli B, Laudisi A, Vidiri A, Conti L, Cappuzzo F. *Future Oncol.* 2022 Dec;18(40):4457-4464. doi: 10.2217/fon-2022-0913. Epub 2023 Mar 22. PMID: 36946237 Review.
153. Cosmai L., Porta C., Privitera C., Gesualdo L., Procopio G., **Gori S**, Laghi A. Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies. *ESMO Open* 2020 Mar;5(2):e000618.
154. Frassoldati A., Biganzoli L., Bordonaro R., Cinieri S., Conte P., Laurentis M.D., Mastro L.D., **Gori S**, Lauria R., Marchetti P., Michelotti A., Montemurro F., Naso G., Pronzato P., Puglisi F., Tondini C.A. Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: Extending endocrine sensitivity. *Future Oncology* 2020 Feb;16(5):129-145.
155. Cirillo M., Carlucci L., Legramandi L., Baldini E., Sacco C., Zagonel V., Leo S., Di Fabio F., Tonini G., Meacci M.L., Tartarone A., Farci D., Tortora G., Zaninelli M., Valori V.M., Cinieri S., Carrozza F., Barbato E., Fabbri V., Cretella E., Gamucci T., Lunardi G., Zamboni S., Micallo G., Cascinu S., Pinto C., **Gori S**. Oral anticancer

- therapy project: Clinical utility of a specific home care nursing programme on behalf of Italian Association of Medical Oncology (AIOM). *J. Clinical Nursing* 2020 Jan;29(1-2):119-129.
156. Cortellini A., Buti S., Bersanelli M., Giusti R., Perrone F., Di Marino P., Tinari N., De Tursi M., Grassadonia A., Cannita K., Tessitore A., Zoratto F., Veltri E., Malorgio F., Russano M., Anesi C., Zeppola T., Filetti M., Marchetti P., Botticelli A., Cappellini G.C.A., De Galitiis F., Vitale M.G., Rastelli F., Pergolesi F., Berardi R., Rinaldi S., Tudini M., Silva R.R., Pireddu A., Atzori F., Iacono D., Migliorino M.R., Gelibter A., Occhipinti M.A., Martella F., Inno A., **Gori S.**, Bracarda S., Zannori C., Mosillo C., Parisi A., Porzio G., Mallardo D., Fargnoli M.C., Tiseo M., Santini D., Ascierto P.A., Ficorella C. Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study *Oncol Immunology* 2020 Jan 7;9(1):1710389.
 157. Incorvaia L., Castiglia M., Ottini L., **Gori S.**, Russo A., Bazan V. Breast Cancer in men: Oncology Plastic and Cosmetic Surgery of the Male Breast
 158. Monsellato I., Garibaldi E., Cassinotti E., Baldari L., Boni L., Elmore U., Delpini R., Rosati R., Perinotti R., Alongi F., Bertocchi E., **Gori S.**, Ruffo G., Pernazza G., Pulighe F., De Nisco C., Morpurgo E., Contardo T., Mammano E., Perna F., Menegatti B., Coratti A., Buccianti P., Balestri R., Ceccarelli C., Cavaliere D., Solaini L., Ercolani G., Traverso E., Fusco V., Torri V., Orecchia S. Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer - TiMiSNAR-mima: A substudy of the TiMiSNAR Trial. *Trials* 2020 Jul 25;21(1):678
 159. Cagnazzo C., Nanni O., Arizio F., Franchina V., Cenna R., Tabaro G., Vannini F., Procopio G., **Gori S.**, Di Costanzo A. Phase I studies: a test bench for Italian clinical research. *Tumori* 2020 Aug;106(4):295-300.
 160. Monsellato I., Alongi F., Bertocchi E., **Gori S.**, Ruffo G., Cassinotti E., Baldari L., Boni L., Pernazza G., Pulighe F., De Nisco C., Perinotti R., Morpurgo E., Contardo T., Mammano E., Elmore U., Delpini R., Rosati R., Perna F., Coratti A., Menegatti B., Gentili S., Baroffio P., Buccianti P., Balestri R., Ceccarelli C., Torri V., Cavaliere D., Solaini L., Ercolani G., Traverso E., Fusco V., Rossi M., Priora F., Numico G., Franzone P., Orecchia S. Correction to: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR). *BMC Cancer*. 2020 Feb 17;20(1):128.
 161. Petrelli F., Iaculli A., Signorelli D., Ghidini A., Dottorini L., Perego G., Ghidini M., Zaniboni A., **Gori S.**, Inno A. Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis. *J Clin Med*. 2020 May 13;9(5):1458.
 162. Bersanelli M., Giannarelli D., De Giorgi U., Pignata S., Di Maio M., Verzoni E., Clemente A., Guadalupi V., Signorelli D., Tiseo M., Giusti R., Filetti M., Di Napoli M., Calveti L., Cappetta A., Ermacora P., Zara D., Barbieri F., Baldessari C., Scotti V., Mazzoni F., Vecchia A., Guglielmini P.F., Maruzzo M., Rossi E., Grossi F., Casadei C., Cortellini A., Verderame F., Montesarchio V., Rizzo M., Mencoboni M., Zustovich F., Fratino L., Cinieri S., Negrini G., Banzi M., Sorarù M., Zucali P.A., Lacidogna G., Russo A., Battelli N., Fomarin G., Mucciarini C., Bracarda S., Bonetti A., Pezzuolo D., Longo L., Sartori D., Iannopollo M., Cavanna L., Meriggi F., Tassinari D., Corbo C., Gemone A., Prati V., Carnio S., Giordano P., Dicorato A.M., Verusio C., Atzori F., Carrozza F., **Gori S.**, Castro A., Pilotto S., Vaccaro V., Garzoli E., Di Costanzo F., Maiello E., Labianca R., Pinto C., Tognetto M., Buti S. Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. *Ther Adv Med Oncol*. 2020 Nov 2;12:1758835920968463.
 163. Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azavedo J, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantzis V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. *N Engl J Med*. 2021 Jun 24;384(25):2394-2405.
 164. Buti S, Bersanelli M, Perrone F, Tiseo M, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Pergolesi F, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Ferrari M, Vitale MG, Nicolardi L, Chiari R, Rijavec E, Nigro O, Tuzi A, De Tursi M, Di Marino P, Conforti F, Queirolo P, Bracarda S, Macrini S, **Gori S.**, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Santoni M, Patruno L, Porzio G, Ficorella C, Pinato DJ, Ascierto PA, Cortellini A. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. *Eur J Cancer*. 2021 Jan;142:18–28.
 165. Deledda G, Riccardi N, **Gori S.**, Poli S, Giansante M, Geccherle E, Mazzi C, Silva R, Desantis N, Giovannetti AM, Solari A, Confalonieri P, Grazzi L, Sarcletti E, Biffa G, Biagio AD, Sestito C, Keim R, Gangi Hermis AMRD, Mazzoldi M, Failo A, Scaglione A, Faldetta N, Dorangricchia P, Moschetto M, Soto Parra HJ, Faietti J, Profio AD, Rusconi S, Giacomelli A, Marchioreto F, Alongi F, Marchetta A, Molon G, Bisoffi Z, Angheben A. The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The 'ImpACT-COVID-19 for Patients' Multi-Centre Observational Study. *Int J Environ Res Public Health*. 2021 Jan 5;18(1).
 166. Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, Caldara A, Rocca A, **Gori S.**, Piacentini F, Berardi R, Brandes AA, Foglietta J, Villa F, Todeschini R, Tognetto M, Naldi N, Bortesi B, Montemurro F, Ardizzoni A, Boni L, Musolino A. Phase II study of eribulin in combination with gemcitabine for

- the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). *ESMO Open*. 2021 Feb;6(1):100019.
167. Banna GL, Cortellini A, Cortinovis DL, Tiseo M, Aerts JGJV, Barbieri F, Giusti R, Bria E, Grossi F, Pizzutillo P, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Gelibter A, Macerelli M, Rastelli F, Chiari R, Rocco D, **Gori S**, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Filetti M, Montrone M, Citarella F, Marco R, Cantini L, Nigro O, D'Argento E, Buti S, Minuti G, Landi L, Guaitoli G, Lo Russo G, De Toma A, Donisi C, Friedlaender A, De Giglio A, Metro G, Porzio G, Ficorella C, Addeo A. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 $\geq 50\%$ advanced non-small-cell lung cancer. *ESMO Open*. 2021 Apr;6(2):100078.
 168. Guarnieri V, Bassan F, Zagonel V, Milella M, Zaninelli M, Cattelan AM, Vianello A, **Gori S**, Aprile G, Azzarello G, Chiari R, Favaretto A, Oliani C, Scolà A, Pastorelli D, Mandarà M, Zustovich F, Bernardi D, Chiarion-Sileni V, Morandi P, Toso S, Di Liso E, Zampieri S, Caccese M, Zampiva I, Puccetti O, Celestino M, Dieci MV, Conte P, Veneto Oncology Network. Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covid19 study. *Eur J Cancer*. 2021 Apr;147:120–7.
 169. Maruzzo M, La Verde N, Russo A, Marchetti P, Scagnoli S, Gonzato O, Di Maio M, Zagonel V, Galvano A, Lanzetta G, Perrone F, Beretta G, Bordonaro R, Comandone A, Cinieri S, Nicolis F, **Gori S**. Second medical opinion in oncological setting. *Crit Rev Oncol Hematol*. 2021 Apr;160:103282.
 170. Inno A, Maurea N, Metro G, Carbone A, Russo A, **Gori S**. Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports. *Cancer Immunol Immunother*. 2021 Apr 20;
 171. Cortellini A, Cannita K, Tiseo M, Cortinovis DL, Aerts JGJV, Baldessari C, Giusti R, Ferrara MG, D'Argento E, Grossi F, Guida A, Berardi R, Morabito A, Genova C, Antonuzzo L, Mazzoni F, De Toma A, Signorelli D, Gelibter A, Targato G, Rastelli F, Chiari R, Rocco D, **Gori S**, De Tursi M, Mansueto G, Zoratto F, Filetti M, Bracarda S, Citarella F, Russano M, Cantini L, Nigro O, Buti S, Minuti G, Landi L, Ricciardi S, Migliorino MR, Natalizio S, Simona C, De Filippis M, Metro G, Adamo V, Russo A, Spinelli GP, Di Maio M, Banna GL, Friedlaender A, Addeo A, Pinato DJ, Ficorella C, Porzio G. Post-progression outcomes of NSCLC patients with PD-L1 expression $\geq 50\%$ receiving first-line single-agent pembrolizumab in a large multicentre real-world study. *Eur J Cancer*. 2021 May;148:24–35.
 172. Galanti D, Inno A, La Vecchia M, Borsellino N, Incorvaia L, Russo A, **Gori S**. Current treatment options for HER2-positive breast cancer patients with brain metastases. *Crit Rev Oncol Hematol*. 2021 May;161:103329.
 173. Silvestris N, Argentiero A, Natalicchio A, D'Oronzo S, Beretta GD, Acquati S, Adinolfi V, Di Bartolo P, Danesi R, Faggiano A, Ferrari P, Gallo M, **Gori S**, Morviducci L, Russo A, Tuveri E, Zatelli MC, Montagnani M, Giorgino F. Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper. *ESMO Open*. 2021 May 10;6(3):100153.
 174. Gallo M, Adinolfi V, Morviducci L, Acquati S, Tuveri E, Ferrari P, Zatelli MC, Faggiano A, Argentiero A, Natalicchio A, D'Oronzo S, Danesi R, **Gori S**, Russo A, Montagnani M, Beretta GD, Di Bartolo P, Silvestris N, Giorgino F. Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper. *ESMO Open*. 2021 May 18;6(3):100155.
 175. Inno A, Chiampán A, Lanzoni L, Verzè M, Molon G, **Gori S**. Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients. *Front Cardiovasc Med*. 2021 May 28;8:652186.
 176. Buti S, Bersanelli M, Perrone F, Bracarda S, Di Maio M, Giusti R, Nigro O, Cortinovis DL, Aerts JGJV, Guaitoli G, Barbieri F, Ferrara MG, Bria E, Grossi F, Bareggi C, Berardi R, Torniai M, Cantini L, Sforza V, Genova C, Chiari R, Rocco D, Della Gravara L, **Gori S**, De Tursi M, Di Marino P, Mansueto G, Zoratto F, Filetti M, Citarella F, Russano M, Mazzoni F, Garassino MC, De Toma A, Signorelli D, Gelibter A, Siringo M, Follador A, Bisonni R, Tuzi A, Minuti G, Landi L, Ricciardi S, Migliorino MR, Tabbò F, Olmetto E, Metro G, Adamo V, Russo A, Spinelli GP, Banna GL, Addeo A, Friedlaender A, Cannita K, Porzio G, Ficorella C, Carmisciano L, Pinato DJ, Mazzaschi G, Tiseo M, Cortellini A. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. *Eur J Cancer*. 2021 Jun;150:224–31.
 177. Franchina V, Cagnazzo C, Di Costanzo A, Arizio F, Frazzetto AME, **Gori S**, Cenna R, Nicolis F, Procopio G, Adamo V, La Verde N, Nanni O. Patient associations and clinical oncology research: how much does a patient's voice really matter? *Expert Rev Pharmacoecon Outcomes Res*. 2021 Jun;21(3):433–40.
 178. Petrelli F, Inno A, Ghidini A, **Gori S**, Bersanelli M. Efficacy of immune checkpoint inhibitors in elderly patients aged ≥ 75 years. *Cancer Immunol Immunother*. 2021 Jun;70(6):1777–80.
 179. Varrassi G, Coluzzi F, Guardamagna VA, Puntillo F, Sotgiu G, Vellucci R, Rational Use of Analgesics (RUA) Group. Personalizing Cancer Pain Therapy: Insights from the Rational Use of Analgesics (RUA) Group. *Pain Ther*. 2021 Jun;10(1):605–17.
 180. Russano M, Cortellini A, Giusti R, Russo A, Zoratto F, Rastelli F, Gelibter A, Chiari R, Nigro O, De Tursi M, Bracarda S, **Gori S**, Grossi F, Bersanelli M, Calvetti L, Di Noia V, Scartozzi M, Di Maio M, Bossi P, Falcone A, Citarella F, Pantano F, Ficorella C, Filetti M, Adamo V, Veltri E, Pergolesi F, Occhipinti MA, Nicolardi L, Tuzi A, Di Marino P, Macrini S, Inno A, Ghidini M, Buti S, Aprile G, Lai E, Audisio M, Intagliata S, Marconcini R, Brocco D, Porzio G, Piras M, Rijavec E, Simionato F, Natoli C, Tiseo M, Vincenzi B, Tonini G, Santini D. Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors

- leading to treatment discontinuation. *Cancer Immunol Immunother*. 2022 Apr;71(4):865-874. doi: 10.1007/s00262-021-03045-9. Epub 2021 Aug 31.
181. Incorvaia L, Madonia G, Corsini LR, Cucinella A, Brando C, Gagliardo C, Santoni M, Fanale D, Inno A, Fazio I, Foti G, Galia M, Badalamenti G, Bazan V, Russo A, **Gori S**. Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors. *Crit Rev Oncol Hematol*. 2021 Jun 3;103390.
 182. Russo A, Incorvaia L, Del Re M, Malapelle U, Capoluongo E, Gristina V, Castiglia M, Danesi R, Fassan M, Giuffrè G, **Gori S**, Marchetti A, Normanno N, Pinto C, Rossi G, Santini D, Sartore-Bianchi A, Silvestris N, Tagliaferri P, Troncone G, Cinieri S, Beretta GD. The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM-SIAPEC-IAP-SIBioC-SIC-SIF Italian Scientific Societies. *ESMO Open*. 2021 Jun 3;6(3):100164.
 183. Santini D, Zeppola T, Russano M, Citarella F, Anesi C, Buti S, Tucci M, Russo A, Sergi MC, Adamo V, Stucci LS, Bersanelli M, Mazzaschi G, Spagnolo F, Rastelli F, Giorgi FC, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Siringo M, Ferrari M, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Ghidini M, Nigro O, Grossi F, De Tursi M, Di Marino P, Pala L, Queirolo P, Bracarda S, Macrini S, **Gori S**, Inno A, Zoratto F, Tanda ET, Mallardo D, Vitale MG, Talbot T, Ascierto PA, Pinato DJ, Ficorella C, Porzio G, Cortellini A. PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. *J Transl Med*. 2021 Jun 24;19(1):270.
 184. Apolone G, Ardizzoni A, Biondi A, Bortolami A, Cardone C, Ciniselli CM, Conte P, Crippa C, de Braud F, Duca M, **Gori S**, Gritti G, Inno A, Luksch R, Lussana F, Maio M, Pasello G, Perrone F, Rambaldi A, Rossi G, Signorelli D, Soverini G, Valente M, Verderio P, Buzzetti G. Skip pattern approach toward the early access of innovative anticancer drugs. *ESMO Open*. 2021 Aug;6(4):100227.
 185. Foti G, Serra G, Iacono V, Marocco S, Bertoli G, **Gori S**, Zorzi C. Identification of Non-Traumatic Bone Marrow Oedema: The Pearls and Pitfalls of Dual-Energy CT (DECT). *Tomography*. 2021 Aug 26;7(3):387–96.
 186. Guameri V, Giorgi CA, Cinieri S, Bengala C, Mariani G, Bisagni G, Frassoldati A, Zamagni C, De Rossi C, Amoroso V, Andreatta C, Ferro A, Zambelli A, **Gori S**, Garrone O, Dieci MV, Orlando L, Pastina I, Beninato T, Moretti G, Genovesi E, Cinefra M, Vicini R, Magni G, De Salvo GL, Conte P. Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial. *Eur J Cancer*. 2021 Sep;154:21–9.
 187. Inno A, Roviello G, Ghidini A, Luciani A, Catalano M, **Gori S**, Petrelli F. Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis. *Crit Rev Oncol Hematol*. 2021 Sep;165:103434.
 188. Rosati G, Lonardi S, Galli F, Di Bartolomeo M, Ronzoni M, Zampino MG, Banzi M, Zaniboni A, Paisini F, Bozzarelli S, Garattini SK, Ferrari D, Montesarchio V, Mambrini A, Ciuffreda L, Galli F, Pusceddu V, Carlomagno C, Bidoli P, Amoroso D, CBochicchio AM, Frassinetti L, Corsi D, Bilancia D, Pastorino A, De Stefano A, Labianca R; TOSCA (Three or Six Colon Adjuvant) investigators. TOSCA (Three or Six Colon Adjuvant) investigators: D Bilancia, G Rosati, V Montesarchio, R V Iaffaioli, G Nasti, B Daniele, V Zagonel, S Lonardi, N Pella, G Aprile, F Pasini, Roma P Marchetti, A Romiti, L Ciuffreda, D Ferrari, P Foa, A Zaniboni, R Labianca, S Mosconi, A Sobrero, P Bidoli, M Cazzaniga, G D Beretta, D C Corsi, E Cortesi, S Barni, F Petrelli, P Allione, A M D'Arco, G Valmadre, E Piazza, E Veltri, G Vietti Ramus, L Giustini, S Tumulo, S Cascinu, C Granetto, F Testore, M Giordano, M Moroni, M Di Seri, A Nuzzo, L Angelelli, S Gori, G Farina, M Aglietta, R Franchi, M Comandé, P Giordani, G Tonini, E Bucci, A Ballestrero, M Benasso, C Graiff, S Bravi, O Caffo, R R Silva, L Frontini, S Rota, L Cozzi, M Cantore, E Maiello, S Cinieri, N Silvestris, S Romito, V Gebbia, M Banzi, A Santoro, F Artioli, R Mattioli, A Contu, F Di Costanzo, F Leonardi, L Cavanna, R Passalacqua, D Amoroso, P Sozzi, M D'Amico, D Amadori, L Frassinetti, D Turci, A Ravaioli, E Pasquini, A Gambi, M Faedi, G Cruciani, E Bajetta, M Di Bartolomeo, L Gianni, M Ronzoni, M T Ionta, B Massidda, M Scartozzi, M G Zampino, A M Bochicchio, A Ciarlo, A Di Leo, S Frustaci, G Rangoni, A Arizzoia, L Pavesi, C Verusio, G Pinotti, A Iop, E Bajetta, S De Placido, C Carlomagno, V Adamo, C Ficorella, D Natale, E Greco, E Rulli, F Galli, D Poli, L Porcu, V Torri. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. *Eur J Cancer* 2021; 148:190-201.
 190. Guameri V, Giorgi CA, Cinieri S, Bengala C, Mariani G, Bisagni G, Frassoldati A, Zamagni C, De Rossi C, Amoroso V, Andreatta C, Ferro A, Zambelli A, **Gori S**, Garrone O, Dieci MV, Orlando L, Pastina I, Beninato T, Moretti G, Genovesi E, Cinefra M, Vicini R, Magni G, De Salvo GL, Conte P. Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial. *Eur J Cancer*. 2021 Sep;154:21-29.
 191. Russo A, Incorvaia L, Malapelle U, Del Re M, Capoluongo E, Vincenzi B, Chiari R, Cortesi L, Danesi R, Florena AM, Fontanini G, **Gori S**, Marchetti A, Normanno N, Pinto C, Sangiolo D, Silvestris N, Tagliaferri P, Tallini G, Cinieri S, Beretta GD. The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies. *Crit Rev Oncol Hematol*. 2021 Sep;165:103436.
 192. Vecchia A, Sforza V, Vattermi E, Inno A, Kinspergher S, Dipasquale M, **Gori S**, Morabito A, Baldi I, Caffo O. Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab. *Immunotherapy*. 2021 Sep;13(13):1093–103.
 193. Del Mastro L, Mansutti M, Bisagni G, Ponzzone R, Durando A, Amaducci L, Campadelli E, Cognetti F, Frassoldati A, Michelotti A, Mura S, Urracci Y, Sanna G, **Gori S**, De Placido S, Garrone O, Fabi A, Barone C, Tamberi S, Bighin C, Puglisi F, Moretti G, Arpino G, Ballestrero A, Poggio F, Lambertini M, Montemurro F, Bruzzi

- P, Gruppo Italiano Mammella investigators. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol.* 2021 Oct;22(10):1458–67.
194. Caminiti C, Annunziata MA, Verusio C, Pinto C, Airolidi M, Aragona M, Caputo F, Cinieri S, Giordani P, **Gori S**, Mattioli R, Novello S, Pazzola A, Procopio G, Russo A, Sarobba G, Zerilli F, Diodati F, Iezzi E, Maglietta G, Passalacqua R. Effectiveness of a Psychosocial Care Quality Improvement Strategy to Address Quality of Life in Patients With Cancer: The HuCare2 Stepped-Wedge Cluster Randomized Trial. *JAMA Netw Open.* 2021 Oct 1;4(10):e2128667.
 195. Caprara G, Tieri M, Fabi A, Guameri V, Falci C, Dieci MV, Turazza M, Ballardini B, Bin A, Cinieri S, Vici P, Montagna E, Zamagni C, Mazzi C, Modena A, Marchetti F, Verzè M, Ghelfi F, Titta L, Nicolis F, **Gori S**. Results of the ECHO (Eating habits CHanges in Oncologic patients) Survey: An Italian Cross-Sectional Multicentric Study to Explore Dietary Changes and Dietary Supplement Use, in Breast Cancer Survivors. *Front Oncol.* 2021 Nov;11:705927.
 196. Natalicchio A, Faggiano A, Zatelli MC, Argentiero A, D'Oronzo S, Marrano N, Beretta GD, Acquati S, Adinolfi V, Di Bartolo P, Danesi R, Ferrari P, **Gori S**, Morviducci L, Russo A, Tuveri E, Montagnani M, Gallo M, Silvestris N, Giorgino F. Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. *Crit Rev Oncol Hematol.* 2022 Jan;169:103572.
 197. Russo A, Inconvaia L, Capoluongo E, Tagliaferri P, Galvano A, Del Re M, Malapelle U, Chiari R, Conte P, Danesi R, Fassan M, Ferrara R, Genuardi M, Ghiorzo P, **Gori S**, Guadagni F, Marchetti A, Marchetti P, Midiri M, Normanno N, Passiglia F, Pinto C, Silvestris N, Tallini G, Vatrano S, Vincenzi B, Cinieri S, Beretta G. The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. *Crit Rev Oncol Hematol.* 2022 Jan;169:103567.
 198. Cortellini A, Giusti R, Filetti M, Citarella F, Adamo V, Santini D, Buti S, Nigro O, Cantini L, Di Maio M, Aerts JGJV, Bria E, Bertolini F, Ferrara MG, Ghidini M, Grossi F, Guida A, Berardi R, Morabito A, Genova C, Mazzoni F, Antonuzzo L, Gelibter A, Marchetti P, Chiari R, Macerelli M, Rastelli F, Della Gravara L, **Gori S**, Tuzi A, De Tursi M, Di Marino P, Mansueto G, Pecci F, Zoratto F, Ricciardi S, Migliorino MR, Passiglia F, Metro G, Spinelli GP, Banna GL, Friedlaender A, Addeo A, Ficorella C, Porzio G, Tiseo M, Russo A, Russano M, Pinato DJ. High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. *J Hematol Oncol.* 2022 Jan 21;15(1):9.
 199. Banna GL, Tiseo M, Cortinovis DL, Facchinetti F, Aerts JGJV, Baldessari C, Giusti R, Bria E, Grossi F, Berardi R, Morabito A, Catino A, Genova C, Mazzoni F, Gelibter A, Rastelli F, Macerelli M, Chiari R, **Gori S**, Mansueto G, Citarella F, Cantini L, Rijavec E, Bertolini F, Cappuzzo F, De Toma A, Friedlaender A, Metro G, Pensieri MV, Porzio G, Ficorella C, Pinato DJ, Cortellini A, Addeo A. Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 $\geq 50\%$ metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. *Thorac Cancer.* 2022 Feb;13(3):483–8.
 200. Cantini L, Mentrasti G, Russo GL, Signorelli D, Pasello G, Rijavec E, Russano M, Antonuzzo L, Rocco D, Giusti R, Adamo V, Genova C, Tuzi A, Morabito A, **Gori S**, Verde NL, Chiari R, Cortellini A, Cognigni V, Pecci F, Indini A, De Toma A, Zattarin E, Oresti S, Pizzutilo EG, Frega S, Erbetta E, Galletti A, Citarella F, Fancelli S, Caliman E, Della Gravara L, Malapelle U, Filetti M, Piras M, Toscano G, Zullo L, De Tursi M, Di Marino P, D'Emilio V, Cona MS, Guida A, Caglio A, Salerno F, Spinelli G, Bennati C, Morgillo F, Russo A, Dellepiane C, Vallini I, Sforza V, Inno A, Rastelli F, Tassi V, Nicolardi L, Pensieri V, Emili R, Roca E, Migliore A, Galassi T, Rocchi MLB, Berardi R. Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario. *ESMO Open.* 2022 Apr;7(2):100406.
 201. Russano M, Cortellini A, Giusti R, Russo A, Zoratto F, Rastelli F, Gelibter A, Chiari R, Nigro O, De Tursi M, Bracarda S, **Gori S**, Grossi F, Bersanelli M, Calvetti L, Di Noia V, Scartozzi M, Di Maio M, Bossi P, Falcone A, Citarella F, Pantano F, Ficorella C, Filetti M, Adamo V, Veltri E, Pergolesi F, Occhipinti MA, Nicolardi L, Tuzi A, Di Marino P, Macrini S, Inno A, Ghidini M, Buti S, Aprile G, Lai E, Audisio M, Intagliata S, Marconcini R, Brocco D, Porzio G, Piras M, Rijavec E, Simionato F, Natoli C, Tiseo M, Vincenzi B, Tonini G, Santini D. Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. *Cancer Immunol Immunother.* 2022 Apr;71(4):865–74.
 202. Tarantini L, Foglietta J, **Gori S**, Pinto C, Russo A, Navazio A. Hormone therapy, cardio-metabolic profile and cardiotoxicity. Still a dark side of cardio-oncology. Part 1: Breast cancer. *G Ital Cardiol (Rome).* 2022 Apr;23(4):286–94.
 203. Dieci MV, Azzarello G, Zagonel V, Bassan F, **Gori S**, Aprile G, Chiarion-Sileni V, Lonardi S, Oliani C, Zaninelli M, Chiari R, Favaretto A, Pavan A, Di Liso E, Mioranza E, Baldoni A, Bergamo F, Maruzzo M, Zampieri S, Inno A, Graziani F, Sinigaglia G, Celestino M, Conte P, Guameri V, Veneto Oncology Network. Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID study. *Eur J Cancer.* 2022 May;167:81–91.
 204. Oriacchio A, Guastoni C, Beretta GD, Cosmai L, Galluzzo M, **Gori S**, Grassedonio E, Inconvaia L, Marcantoni C, Netti GS, Passamonti M, Porta C, Procopio G, Rizzo M, Roma S, Romanini L, Stacul F, Casinelli A. SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing

- contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM). *Radiol Med.* 2022 May;127(5):534–42.
205. Gori S, Modena A, Foglietta J, Verzè M, Inno A, Casarin A, Russo A, Nicolis F. Adherence to oral hormonal anticancer agents in breast cancer. *Tumori.* 2022 May 21;03008916221096183.
 206. Russo A, Incorvaia L, Capoluongo E, Tagliaferri P, Gori S, Cortesi L, Genuardi M, Turchetti D, De Giorgi U, Di Maio M, Barberis M, Dessena M, Del Re M, Lapini A, Luchini C, Jerezek-Fossa BA, Sapino A, Cinieri S, Italian Scientific Societies. Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. *ESMO Open.* 2022 Jun;7(3):100459.
 207. Löffler MW, Gori S, Izzo F, Mayer-Mokler A, Ascierto PA, Königsrainer A, Ma YT, Sangro B, Francque S, Vonghia L, Inno A, Avallone A, Ludwig J, Alcoba DD, Flohr C, Aslan K, Mendrzyk R, Schuster H, Borrelli M, Valmori D, Chaumette T, Heidenreich R, Gouttefangeas C, Forlani G, Tagliamonte M, Fusco C, Penta R, Iñarrairaegui M, Gnad-Vogt U, Reinhardt C, Weinschenk T, Accolla RS, Singh-Jasuja H, Rammensee HG, Buonaguro L. Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. *Clin Cancer Res.* 2022 Jun 13;28(12):2555–66.
 208. Miglietta F, Cinquini M, Dieci MV, Cortesi L, Criscitiello C, Montemurro F, Del Mastro L, Zambelli A, Biganzoli L, Levaggi A, Delle Piane C, Marchiò C, Calabrese M, Fortunato L, Franco P, Meduri B, Fittipaldo VA, Gori S. PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology. *Breast.* 2022 Oct 29;66:293–304.
 209. Faggiano A, Mazzilli R, Natalicchio A, Adinolfi V, Argentiero A, Danesi R, D'Oronzo S, Fogli S, Gallo M, Giuffrida D, Gori S, Montagnani M, Ragni A, Renzelli V, Russo A, Silvestris N, Franchina T, Tuveri E, Cinieri S, Colao A, Giorgino F, Zatelli MC, Oncological Endocrinology research group of the Italian Society of Endocrinology. Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. *Crit Rev Oncol Hematol.* 2022 Dec;180:103826.
 210. Geyer CE, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Amedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafty F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnani M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓP, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martínez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ, OlympiA Clinical Trial Steering Committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. *Ann Oncol.* 2022 Dec;33(12):1250–68.
 211. Contoli B, Possenti V, Minardi V, Gori S, Beretta G, Masocco M. Modifiable Risk Factors, Health Profile and Well-Being of the Elderly Diagnosed with Cancer in Italy: Passi d'Argento Surveillance System 2016-2019 Results. *Cancers (Basel).* 2022 Dec 14;14(24):6185.
 212. Murri A, Vitucci D, Tranchita E, Grazioli E, Gori S, Modena A, Turazza M, Filippini R, Galeazzi S, Verzè M, Frittelli P, Corsi DC, Nicolis F, Parisi A, Cerulli C. 'OPERATION PHALCO'-Adapted Physical Activity for Breast Cancer Survivors: Is It Time for a Multidisciplinary Approach? *Cancers (Basel).* 2022 Dec 21;15(1):34.
 213. Landi L, Delmonte A, Bonetti A, Pasello G, Metro G, Mazzoni F, Borra G, Giannarelli D, Andrikou K, Mangiola D, Gori S, D'Andrea MR, Minuti G, Resuli B, Laudisi A, Vidiri A, Conti L, Cappuzzo F. Combi-TED: a new trial testing Tedopi® with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line. *Future Oncol.* 2022 Dec;18(40):4457–64.
 214. N Colombo, A Gadducci, J Sehouli, E Rulli, J Mäenpää, C Sessa, A Montes, N B Ottevanger, R Berger, I Vergote, M D'Incalci, C Churrua Galaz, R Chekerov, G B Nyvang, S Riniker, R Herbertson, R Fossati 4, M P Barretina-Ginesta 16, M Deryal, M R Mirza 18, E Biagioli 19, M Iglesias 20, G Funari 4, M Romeo 21, G Tasca 22, B Pardo 23, G Tognon 24, M J Rubio-Pérez 25, A DeCensi 26, U De Giorgi 27, P Zola 28, P Benedetti Panici 29, M Aglietta 30, V Arcangeli 31, C Zamagni 32, A Bologna 33, A Westermann, V Heinzlmann-Schwarz, I Tsublak, P Wimberger, A Poveda; INOVATYON study group Collaborators
 215. Nicoletta Colombo, Angiolo Gadducci, Eliana Rulli, Elena Biagioli, Roldano Fossati, Giuseppe Funari, Luciano Carlucci, Davide Poli, Maria Clara Caudana, Giulia Tasca, Maria Ornella Nicoletto, Germana Tognon, Andrea DeCensi, Ugo De Giorgi, Paolo Zola, Dionyssios Katsaros, Pierluigi Benedetti Panici, Innocenza Palaia, Massimo Aglietta, Valentina Arcangeli, Claudio Zamagni, Alessandra Bologna, Alessandro Bertolini, Cinzia Caroti, Milena Bruzzone, Nicoletta Donadello, Gianna Di Costanzo, Alberto Zaniboni, Daniela Surico, Roberta Buosi, Enrico Cortesi, Elena Zafarana, Vittorio Fusco, Laura Zavallone, Teresa Gamucci, Filomena Narducci, Valentina Musacchi, Luciana Babilonti, Annamaria Ferrero, Luigi Cavanna, Roberto Sabbatini, Stefano Tamberi, Maria Rosa Gentili, Grazia Artioli, Antonio Ardizzoia, Alessia Caldara, Zuzana Sirotová, Clelia Casartelli, Michele Aieta, Saverio Cinieri, Elvira De Marino, Stefania Gori, Francesco Ferrà, Livio Blasi, Massimiliano Alù, Sabino De Placido, Carlo Milandri, Cristina Churrua Galaz, Maria Pilar Barretina-Ginesta, Isabel Bover, Margarita Romeo, Beatriz Pardo, Maria Jesus Rubio-Pérez, Andrés Poveda, Ana Santaballa, Raúl Márquez, Jesus

- Alarcon, Cristina Caballero-Diaz, Nuria Ruiz Miravet, Eugenia Ortega, Maria Angels Arcusa Lanza, Silvia Catot Tort, Elena Garcia Martinez, Regina Girones, Yolanda Garcia, Cesar Mendiola, Ana Beatriz Sanchez, Elena Garcia Martinez, Jalid Sehoul, Mustafa Deryal, Pauline Wimberger, Georg Heinrich, Ingo Runnebaum, Fabian Trillsch, Gülden Oskay-Özcelik, Maike de Wit, Eva-Maria Grischke, Dirk Bauerschlag, Florian Heitz, Alexander Mustea, Tanja Fehm, Andrea Heider, Max Dieterich, Martina Groop-Meier, Marco Battista, Achim Woeckel, Ivo Meinhold-Heerlein, Ana Montes, Rebecca Herbertson, Emma Hudson, Rebecca Bowen, Ignace Vergote, Lionel D'Hondt, Peter Vuylsteke, Christof Vulsteke, Petronella-Beatrix Ottevanger, Anneke M Westermann, Cristiana Sessa, Salome Riniker, Viola Heinzlmann-Schwarz, Roger Von Moos, Elena Kralidis, Michael Mueller, Stefan Aebi, Catrina Uhlmann Nussbaum, Mathias Fehr, Andreas Müller, Christian Taverna, Johanna Mäenpää, Gitte-Bettina Nyvang, Mansoor Raza Mirza, Gunnar B Kristensen, Anne Gry Bentzen, Bent Fiane, Ulla Puistola, Maarit Anttila, Christian Marth, Regina Berger, Edgar Petru, Christian Schauer, Alexander Reinthaller. INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line; INOVATYON study group Eur J Cancer 2023; 128 (8):1503-1513.
216. Inno A, Bogina G, Settanni G, Salgarello M, Foti G, Pomari C, Picece V, **Gori S**. First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression. Drug Target Insights. 2023;17:110–3.
 217. Inno A, Lattuada E, Foti G, **Gori S**. Chemo-immunotherapy for metastatic non-squamous NSCLC in a patient with HIV infection: A case report. Front Oncol. 2023;13:1053497.
 218. Inno A, Marchetti F, Valerio M, Giaj Levra N, Alongi F, Foti G, **Gori S**. Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report. Drug Target Insights. 2023;17:90–1.
 219. Piubelli C, Valerio M, Verzè M, Nicolis F, Mantoan C, Zamboni S, Perandin F, Rizzi E, Tais S, Degani M, Caldrea S, Gobbi FG, Bisoffi Z, **Gori S**. Humoral Effect of SARS-CoV-2 mRNA vaccination with booster dose in solid tumor patients with different anticancer treatments. Front Oncol. 2023;13:1089944.
 220. Inno A, Peri M, Turazza M, Bogina G, Modena A, Massocco A, Pezzella M, Valerio M, Mazzola R, Olivari L, Severi F, Foti G, Mazzi C, Marchetti F, Lunardi G, Salgarello M, Russo A, **Gori S**. The predictive and prognostic role of metabolic and volume-based parameters of positron emission tomography/computed tomography as non-invasive dynamic biological markers in early breast cancer treated with preoperative systemic therapy. Front Oncol. 2023 Jan 4;12:976823.
 221. Tralongo P, Cappucco F, **Gori S**, Donato V, Beretta G, Elia A, Romano F, Iacono M, Tralongo AC, Bordonaro S, Di Mari A, Giuliano SR, Buccafusca G, Careri MC, Santoro A. Clinicians' and Patients' Perceptions and Use of the Word 'Cured' in Cancer Care: An Italian Survey. Curr Oncol. 2023 Jan 17;30(2):1332–53.
 222. Lambertini M, Blondeaux E, Bisagni G, Mura S, De Placido S, De Laurentis M, Fabi A, Rimanti A, Michelotti A, Mansutti M, Russo A, Montemurro F, Frassoldati A, Durando A, **Gori S**, Turletti A, Tamperi S, Urracci Y, Fregatti P, Razeti MG, Caputo R, De Angelis C, Sanna V, Gasparini E, Agostinetto E, de Azambuja E, Poggio F, Boni L, Del Mastro L. Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies. eClinicalMedicine. 2023 May 1;59:101931.
 223. **Gori S**, Modena A, Foglietta J, Verzè M, Inno A, Casarin A, Russo A, Nicolis F. Adherence to oral hormonal anticancer agents in breast cancer. Tumori. 2023 Jun;109(3):262–8.
 224. Muscaritoli M, Modena A, Valerio M, Marchetti P, Magarotto R, Quadrini S, Narducci F, Tonini G, Grassani T, Cavanna L, Di Nunzio C, Citterio C, Ocellini M, Strippoli A, Chiurazzi B, Frassoldati A, Altavilla G, Lucenti A, Nicolis F, **Gori S**. The Impact of Nutritional Status at First Medical Oncology Visit on Clinical Outcomes: The NUTRIONCO Study. Cancers (Basel). 2023 Jun 15;15(12):3206.
 225. Inno A, Bogina G, Settanni G, Foti G, Tessari R, **Gori S**. Mucoepidermoid Carcinoma of the Lung Harboring MET Exon 14 Skipping Mutation Treated With Tepotinib: A Case Report. JCO Precis Oncol. 2023 Jul;7:e2300136.
 226. Inno A, Tarantini L, Parrini I, Spallarossa P, Maurea N, Bisceglia I, Silvestris N, Russo A, **Gori S**. Cardiovascular Effects of Immune Checkpoint Inhibitors: More Than Just Myocarditis. Curr Oncol Rep. 2023 Jul;25(7):743–51.
 227. Renzelli V, Gallo M, Morviducci L, Marino G, Ragni A, Tuveri E, Faggiano A, Mazzilli R, Natalicchio A, Zatelli MC, Montagnani M, Fogli S, Giuffrida D, Argentiero A, Danesi R, D'Oronzo S, **Gori S**, Franchina T, Russo A, Monami M, Sciacca L, Cinieri S, Colao A, Avogaro A, Di Cianni G, Giorgino F, Silvestris N. Polybrominated Diphenyl Ethers (PBDEs) and Human Health: Effects on Metabolism, Diabetes and Cancer. Cancers (Basel). 2023 Aug 24;15(17):4237.
 228. **Gori S**, Fabi A, Angiolini C, Turazza M, Salvini P, Ferretti G, Cretella E, Gianni L, Bighin C, Toss A, Zamagni C, Vici P, De Rossi C, Russo A, Bisagni G, Frassoldati A, Borgato L, Cariello A, Cappelletti C, Bordonaro R, Cinieri S, Modena A, Valerio M, Alvisi MF, De Simone I, Galli F, Rulli E, Santoni A, Nicolis F. Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE Study. Cancers (Basel). 2023 Oct 4;15(19):4852.
 229. Inno A, Picece V, Bogina G, Settanni G, Viassolo V, Salgarello M, **Gori S**. Niraparib for the Treatment of Metastatic NSCLC in a Patient With BRCA2 Germinal Mutation: A Case Report. Clinical Lung Cancer [Internet]. 2023 Oct 29; Available from: <https://www.sciencedirect.com/science/article/pii/S1525730423002255>

230. Metro G, Gariazzo E, Costabile S, Baglivo S, Roila F, Colamartini F, Palumbo B, Chiarini P, **Gori S**, Conti A, Marcomigni L, Bellezza G, Lunardi G. Repotrectinib's Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer. *Oncol Ther*. 2023 Nov 16;
231. Pellegrino B, Tommasi C, Serra O, **Gori S**, Cretella E, Ambroggi M, Frassoldati A, Bisagni G, Casarini C, Bria E, Carbognin L, Fiorio E, Mura A, Zamagni C, Gianni L, Zambelli A, Montemurro F, Tognetto M, Todeschini R, Missale G, Campanini N, Silini EM, Maglietta G, Musolino A. Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016). *J Immunother Cancer*. 2023 Nov 28;11(11):e007667.
232. Ceccaroni M, Roviglione G, Bruni F, Dababou S, Venier M, Zorzi C, Salgarello M, Ruffo G, Alongi F, **Gori S**, Driul L, Uccella S, Barra F. 'Things Have Changed'-Laparoscopic Cytoreduction for Advanced and Recurrent Ovarian Cancer: The Experience of a Referral Center on 108 Patients. *Cancers (Basel)*. 2023 Dec 6;15(24):5726.
233. Conte B, Boni L, Bisagni G, Durando A, Sanna G, **Gori S**, Garrone O, Tamberi S, De Placido S, Schettini F, Pazzola A, Ponzone R, Montemurro F, Lunardi G, Notaro R, De Angioletti M, Turletti A, Mansutti M, Puglisi F, Frassoldati A, Porpiglia M, Fabi A, Generali D, Scognamiglio G, Rossi M, Brasó-Maristany F, Prat A, Cardinali B, Piccioli P, Serra M, Lastraoli S, Bighin C, Poggio F, Lambertini M, Del Mastro L. SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials. *Clin Cancer Res*. 2023 Dec 15;29(24):5217–26.
234. Inno A, Vecchia A, Madonia G, Berti A, Bortolotti R, Incorvaia L, Russo A, Caffo O, **Gori S**. Risk of cardiovascular toxicity with combination of immune-checkpoint inhibitors and angiogenesis inhibitors: a meta-analysis. *Front Cardiovasc Med*. 2024;11:1309100.
235. Passiglia F, Lucia Reale M, Lo Russo G, Pasello G, Minuti G, Bulotta A, Galetta D, Pelizzari G, Sini C, Bria E, Roca E, Pilotto S, Genova C, Metro G, Citarella F, Chiari R, Cortinovis D, Delmonte A, Russo A, Tiseo M, Cerea G, Carta A, Scotti V, Vavalà T, Brambilla M, Buffoni L, Buosi R, Catania C, **Gori S**, Grisanti S, Agustoni F, Garbo E, Malapelle U, Novello S. Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program. *Lung Cancer*. 2024 Jan;187:107444.
236. Incorvaia L, Badalamenti G, Novo G, **Gori S**, Cortesi L, Brando C, Cinieri S, Curigliano G, Ricciardi GR, Toss A, Chiari R, Berardi R, Ballatore Z, Bono M, Bazan Russo TD, Gristina V, Galvano A, Damerino G, Blasi L, Bazan V, Russo A. Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD). *ESMO Open*. 2024 Jan 1;9(1):102196.
237. Foti G, Ascenti G, Agostini A, Longo C, Lombardo F, Inno A, Modena A, **Gori S**. Dual-Energy CT in Oncologic Imaging. *Tomography*. 2024 Feb 23;10(3):299.
238. **Gori S**, Zambelli A, Angiolini C, Ferro A, Rose FD, Fabi A, Azzarello G, Bogina G, Cancian M, Valerio M, Cinquini M, Nicolis F, Pappagallo G. Follow-up of breast cancer: why is it necessary to start a Consensus in 2024? *AboutOpen*. 2024 Feb 23;11(1):10–7.
239. Metro G, Gariazzo E, Costabile S, Baglivo S, Roila F, Colamartini F, Palumbo B, Chiarini P, **Gori S**, Conti A, Marcomigni L, Bellezza G, Lunardi G. Repotrectinib's Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer. *Oncol Ther*. 2024 Mar;12(1):163–71.
240. Inno A, Picece V, Bogina G, Settanni G, Viassolo V, Salgarello M, **Gori S**. Niraparib for the Treatment of Metastatic NSCLC in a Patient With BRCA2 Germinal Mutation: A Case Report. *Clinical Lung Cancer*. 2024 Mar 1;25(2):175–9.
241. Amar ID, Franceschini G, Nero C, Pasqua I, Paris I, Orlandi A, **Gori S**, Fabi A, Garganese G, Scambia G, Villa P. Preventing Bone Loss in Breast Cancer Patients: Designing a Personalized Clinical Pathway in a Large-Volume Research Hospital. *J Pers Med*. 2024 Mar 30;14(4):371.
242. Caccese M, Desideri I, Villani V, Simonelli M, Buglione M, Chiesa S, Franceschi E, Gaviani P, Stasi I, Caserta C, Brugnara S, Lolli I, Bennicelli E, Bini P, Cuccu AS, Scoccianti S, Padovan M, **Gori S**, Bonetti A, Giordano P, Pellerino A, Gregucci F, Riva N, Cinieri S, Internò V, Santoni M, Pernice G, Dealis C, Stievano L, Paiar F, Magni G, De Salvo GL, Zagonel V, Lombardi G. REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma. *ESMO Open*. 2024 Apr;9(4):102943.
243. Musacchio L, Palluzzi E, Di Napoli M, Lauria R, Ferrandina G, Angioli R, Bergamini A, Corrado G, Perniola G, Cassani C, Savarese A, **Gori S**, Greco F, De Angelis C, Zafarana E, Giannarelli D, Cinieri S, Mosconi AM, Raspagliesi F, Pignata S, Scambia G, Lorusso D. Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group. *Gynecol Oncol*. 2024 May;184:24–30.
244. Zatelli MC, Faggiano A, Argentiero A, Danesi R, D'Oronzo S, Fogli S, Franchina T, Giorgino F, Marrano N, Giuffrida D, **Gori S**, Marino G, Mazzilli R, Monami M, Montagnani M, Morviducci L, Natalicchio A, Ragni A, Renzelli V, Russo A, Sciacca L, Tuveri E, Aimaretti G, Avogaro A, Candido R, Di Maio M, Silvestris N, Gallo M. Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary group. *Cancer Treat Rev*. 2024 May;126:102734.

245. Pizzutilo EG, Agostara AG, Oresti S, Signorelli D, Stabile S, Lauricella C, Motta V, Amatu A, Ruggieri L, Brambilla M, Occhipinti M, Proto C, Giusti R, Filetti M, Genova C, Barletta G, Gelsomino F, Bennati C, Siringo M, Di Fazio GR, Russano M, Montrone M, Gariazzo E, Roca E, Bordi P, Delmonte A, Scimone A, Belluomini L, Mazzoni F, Carta A, Pelizzari G, Viscardi G, Morgillo F, Gelibter A, **Gori S**, Berardi R, Cortinovis D, Arduini A, Veronese SM, Sartore-Bianchi A, Giannetta LG, Cerea G, Siena S. Activity of osimertinib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO). *ESMO Open*. 2024 Jun;9(6):103592.
246. Giordani E, Allegretti M, Sinibaldi A, Michelotti F, Ferretti G, Ricciardi E, Ziccheddu G, Valenti F, Di Martino S, Ercolani C, Giannarelli D, Arpino G, **Gori S**, Omarini C, Zambelli A, Bria E, Paris I, Buglioni S, Giacomini P, Fabi A. Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients. *J Exp Clin Cancer Res*. 2024 Jun 29;43(1):182.
247. Deledda G, Poli S, Giansante M, Geccherle E, Fantoni G, Romaniello I, Gabriella F, Verzè M, Nicolis F, **Gori S**. The emotional states and associated behavioral responses (flexible-adaptive behaviors vs. inflexible-maladaptive behaviors) of cancer patients during the SARS-CoV-2 outbreak: A multi-center cross-sectional study in Italy. *Cancer Med*. 2024 Jul;13(13):e7442.
248. Valerio M, Inno A, Zambelli A, Cortesi L, Lorusso D, Viassolo V, Verzè M, Nicolis F, **Gori S**. Deep Neural Network Integrated into Network-Based Stratification (D3NS): A Method to Uncover Cancer Subtypes from Somatic Mutations. *Cancers (Basel)*. 2024 Aug 14;16(16):2845.
249. Berardi R, Parisi A, Maruzzo M, Bellani M, Beretta GD, Boldrini M, Cavanna L, **Gori S**, Iannelli E, Mancuso AM, Marinelli M, Martinella V, Musso M, Papa R, Russo A, Tarantino V, Taranto M, Cinieri S. Communication in oncology between healthcare providers, patients, the scientific community, and the media: recommendations from the Italian Association of Medical Oncology (AIOM). *Support Care Cancer*. 2024 Aug 26;32(9):613.
250. Tessari R, Ossato A, Realdon F, Montresor V, Giovagnoni G, Giannini M, Gandini D, Modena A, Inno A, **Gori S**. Rapid Desensitization to Antitumoral Agents. Result from a Retrospective Study, DESARCh. *Hosp Pharm*. 2024 Sep 5;00185787241278702.
251. Zambelli A, Cortesi L, Gaudio M, Arpino G, Bianchini G, Caruso F, Cinieri S, Curigliano G, Del Mastro L, De Placido S, Fabi A, Fortunato L, Generali D, Gennari A, **Gori S**, Grandi G, Guameri V, Klinger M, Livi L, Marchiò C, Palumbo I, Panizza P, Pravettoni G, Pruner G, Puglisi F, Sapino A, Tinteri C, Turchetti D, De Laurentiis M. Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review. *Cancer Treat Rev*. 2024 Aug 26;130:102815.
252. Mennini FS, Marcellusi A, Sciattella P, Scortichini M, Ragonese A, Cattel F, D'Antona R, Del Mastro L, **Gori S**, Perrone G, Migliorini R, Trabucco Aurilio M. Burden of Disease of Breast Cancer in Italy: A Real-World Data Analysis. *PharmacoEconomics Open*. 2024 Nov 23;1-8.
253. **Gori S**, De Rose F, Ferro A, Fabi A, Angiolini C, Azzarello G, Cancian M, Cinquini M, Arecco L, Aristei C, Bernardi D, Biganzoli L, Cariello A, Cortesi L, Cretella E, Criscitello C, De Giorgi U, Carmen De Santis M, Deledda G, Dessena M, Donati S, Dri A, Ferretti G, Foglietta J, Franceschini D, Franco P, Schirone A, Generali D, Gianni L, Giordani S, Grandi G, Cristina Leonardi M, Magno S, Malorni L, Mantoan C, Martorana F, Meattini I, Meduri B, Merlini L, Miglietta F, Modena A, Nicolis F, Palumbo I, Panizza P, Angela Rovera F, Salvini P, Santoro A, Taffurelli M, Toss A, Tralongo P, Turazza M, Valerio M, Verzè M, Vici P, Zamagni C, Curigliano G, Pappagallo G, Zambelli A. Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project. *Cancer Treatment Reviews*. 2024 Dec 1;131:102832.
254. Natalicchio A, Marrano N, Montagnani M, Gallo M, Faggiano A, Zatelli MC, Argentiero A, Del Re M, D'Oronzo S, Fogli S, Franchina T, Giuffrida D, **Gori S**, Ragni A, Marino G, Mazzilli R, Monami M, Morviducci L, Renzelli V, Russo A, Sciacca L, Tuveri E, Cortellini A, Di Maio M, Candido R, Perrone F, Aimaretti G, Avogaro A, Silvestris N, Giorgino F. Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view. *J Endocrinol Invest*. 2024 Dec 1;47(12):2915-28.
- Gori S**, Fabi A, Angiolini C, Turazza M, Salvini P, Ferretti G, Cretella E, Gianni L, Bighin C, Toss A, Zamagni C, Vici P, De Rossi C, Russo A, Bisagni G, Schirone A, Borgato L, Cariello A, Cappelletti C, Bordonaro R, Cinieri S, Modena A, Valerio M, Alvisi MF, De Simone I, Galli F, Rulli E, Santoni A, Verzè M, Nicolis F. Adjuvant systemic therapy in early breast cancer and results of a prospective observational multicenter BRIDE study: patients outcome and adherence to guidelines in cancer clinical practice. *Front Oncol*. 2025;15:1501667.
255. Gallucci G, Larocca M, Navazio A, Turazza FM, Inno A, Canale ML, Oliva S, Besutti G, Tedeschi A, Aschieri D, Russo A, **Gori S**, Silvestris N, Pinto C, Tarantini L. Atherosclerosis and the Bidirectional Relationship Between Cancer and Cardiovascular Disease: From Bench to Bedside, Part 2 Management. *Int J Mol Sci*. 2025 Jan 2;26(1):334.
256. Valerio M, Inno A, **Gori S**. pyBioPortal: a Python package for simplifying cBioPortal data access in cancer research. *JAMIA Open*. 2025 Feb;8(1):ooae146.
257. Cappuzzo F, Ricciuti B, Delmonte A, Bonanno L, Wang X, Lye WK, Görtz A, Andrikou K, Dal Maso A, Minuti G, Papi M, Alessi JV, Di Federico A, Rodig S, Awad MM, Metro G, Attili I, Vitiello F, Pilotto S, **Gori S**, Rossi G, Buglioni S, Giannarelli D, Landi L. MAPK Pathway-Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial. *Clin Cancer Res*. 2025 Mar 17;31(6):1027-36.
258. Gallo M, Lasagna A, Renzelli V, Morviducci L, Cortellini A, Monami M, Marino G, **Gori S**, Verzè M, Ragni A, Tuveri E, Sciacca L, D'Oronzo S, Giuffrida D, Natalicchio A, Giorgino F, Marrano N, Zatelli MC, Montagnani M,

- Felicetti F, Mazzilli R, Fogli S, Franchina T, Argentiero A, Candido R, Perrone F, Aimaretti G, Avogaro A, Silvestris N, Faggiano A. Vaccination of people with solid tumors and diabetes: existing evidence and recommendations. A position statement from a multidisciplinary panel of scientific societies. J Endocrinol Invest. 2025 Apr 23;
259. Crespi V, Delcuratolo MD, Minuti G, Montrone M, Pilotto S, Roca E, Metro G, Leonetti A, Pelizzari G, Genova C, Olmetto E, Cortinovis D, Russo A, Pasello G, Bulotta A, Grossi F, Buosi R, Conte AD, Sini C, Greco C, Morabito A, Pignataro D, Pagano M, **Gori S**, Giannarelli D, Novello S, Passiglia F. Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer. Lung Cancer. 2025 Jun;204:108576.
260. **Gori S**, Fabi A, Procopio G, Airoidi M, Zambelli A, Lanzetta G, Bracarda S, Foglietta J, Leo S, Baggi A, Franzini JM, Valerio M, Verzè M, Nicolis F. Bone Metastases and Skeletal Complications: Information and Involvement of Patients with Cancer in the Treatment Pathway. Oncol Ther. 2025 Jun;13(2):505–17.
261. Arecco L, Blondeaux E, Bruzzzone M, Arpino G, De Angelis C, De Laurentiis M, Caputo R, Fabi A, Sanna V, **Gori S**, Puglisi F, Boni L, Nardin S, Giannubilo I, Perachino M, Borea R, Agostinetto E, de Azambuja E, Lambertini M, Del Mastro L. Prognostic implications of risk definitions from the monarchE and NATALEE trials. J Natl Cancer Inst. 2025 Jun 1;117(6):1198–208.
262. Inno A, Veccia A, D'Argento E, Morgillo F, Pizzutillo EG, Vitiello F, Pavan A, Lombardo F, Russano M, Sforza V, Colamartini F, Genova C, Chiari R, Cristofano A, Delconte A, Vattermi E, Dessi A, Galanti D, Busato S, Palazzolo G, Savastano C, Bianco A, Verderame F, Mazzi C, Marchetti F, Kinspergher S, Occhipinti D, Corte CMD, Piscazzi D, Gilli M, Bria E, Caffo O, **Gori S**. Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study. Cancer Immunol Immunother. 2025 Jul 12;74(8):266.
263. Scafetta R, Donato M, Gullotta C, Guarino A, Fiore C, Sisca L, Speziale E, Troiano R, Foderaro S, Ricozzi V, Iuliani M, Simonetti S, Cavaliere S, Cortellini A, Botticelli A, Scagnoli S, Pisegna S, Criscitiello C, Pedersini R, Sposetti C, Tiberi E, D'Auria G, Vergati M, Mazzotta M, Caputo R, Verrazzo A, Rossino MG, Domati F, Piombino C, Di Lisa FS, Filomeno L, Arcuri T, Puce F, Riva F, Palleschi M, Sirico M, Piras M, Stucci LS, De Lisi D, Orsaria P, Ippolito E, Ramella S, Visani L, Bertini N, Bonaparte I, **Gori S**, Rossi L, Meattini I, Tagliaferri B, Caffo O, Portarena I, Irelli A, Cretella E, Porta C, Bianchini G, Fabbri A, De Giorgi U, Vici P, Toss A, Garrone O, De Laurentiis M, Villa F, Berardi R, Minelli M, Vernieri C, Curigliano G, Vincenzi B, Tonini G, Santini D, Pantano F. Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors. Breast. 2025 Aug; 82:104502.

"Il presente curriculum è redatto ai sensi e nel rispetto degli artt. 19, 46 e 47 del D.P.R. 445/2000 e nella consapevolezza delle sanzioni penali, nel caso di dichiarazioni non veritiere, di formazione o uso di atti falsi, richiamate dall'art. 76 del D.P.R. 445 del 28 dicembre 2000". Autorizzo il trattamento dei miei dati personali presenti nel cv ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali" e del GDPR (Regolamento UE 2016/679).

Negrar di Valpolicella, 29/07/2025

